Document:

EX-4.3

 Exhibit 4.3 

Execution Version 

BERKELEY LIGHTS, INC. 

FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

This Fifth Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made and entered into as of
March 28, 2018, by and among Berkeley Lights, Inc., a Delaware corporation (the “Company”) and the parties listed on Exhibit A attached hereto (the “Investors”). 

RECITALS 
 A. Certain of
the Investors have agreed to purchase from the Company, and the Company has agreed to sell to such Investors (“Series E Investors”), shares of the Company’s Series E Preferred Stock, $0.00005 par value per share (the
“Series E Preferred Stock”) on the terms and conditions set forth in that certain Series E Preferred Stock Purchase Agreement dated of even date herewith by and among the Company and such Investors (as may be amended from
time to time, the “Series E Agreement”). 
 B. It is a condition to the closing of the sale of the Series E
Preferred Stock that the parties hereto execute and deliver this Agreement. 
 C. Certain of the Investors are also holders of outstanding
shares of the Company’s Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and/or
Series D Preferred Stock previously issued by the Company (the “Prior Investors”) and such Prior Investors have been granted certain rights under a Fourth Amended and Restated Investors’ Rights Agreement, dated as of
October 27, 2016 (the “Prior Agreement”), and pursuant to Section 5.1 thereof, the Prior Agreement may be amended by the written consent of the Company and the holders of at least (i) 60% of the Registrable
Securities then outstanding and held by the Major Investors and (ii) 60% of the shares of Common Stock issued or issuable upon conversion of the then outstanding shares of Preferred Stock held by the Investors (as such terms are defined in the Prior
Agreement) (together, the “Requisite Consent”). 
 D. The Company, the undersigned Prior Investors holding the
Requisite Consent and the Series E Investors desire to enter into this Agreement in order to amend and restate the rights and obligations of the Prior Investors under the Prior Agreement, pursuant to the terms thereof, and to grant the Prior
Investors and the Series E Investors the rights set forth in this Agreement, subject to the obligations set forth herein. 
 NOW,
THEREFORE, in consideration of the foregoing recitals and the mutual promises hereinafter set forth, the Investors and the Company hereby agree to enter into this Agreement to amend, restate and replace their rights and obligations under the
Prior Agreement with the rights and obligations set forth in this Agreement. 

 1. DEFINITIONS. For purposes of this Agreement: 

“Affiliate” means, with respect to any specified Person, any other Person who or which, directly or indirectly,
controls, is controlled by, or is under common control with such Person including without limitation any general partner, managing partner, managing member, officer, director or trustee of such Person, or any venture capital fund or registered
investment company now or hereafter existing that is controlled by one or more general partners, managing members or investment adviser of, or shares the same management company or investment adviser with, such Person. For purposes of this
definition, the terms “controlling,” “controlled by,” or “under common control with” shall mean the possession, directly or indirectly, of (a) the power to direct or cause the direction of the management and
policies of a Person, whether through the ownership of voting securities, by contract, or otherwise or (b) the power to elect or appoint at least fifty percent (50%) of the directors, managers, general partners, or persons exercising similar
authority with respect to such Person. 
 “Automatic Shelf Registration Statement” shall have the meaning given to
that term in SEC Rule 405. 
 “Board” means the Board of Directors of the Company. 

“business day” means a weekday on which banks are open for general banking business in New York, New York. 

“Code” means the Internal Revenue Code of 1986, as amended. 

“Common Stock” means shares of the Company’s common stock, par value $0.00005. 

“Damages” means any loss, damage, or liability (joint or several) to which a party hereto may become subject under the
Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, or liability (or any action in respect thereof) arises out of or is based upon (a) any untrue statement or alleged untrue statement of a material
fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, and any free-writing prospectus and any issuer information (as defined
in Rule 433 of the Securities Act) filed or required to be filed pursuant to Rule 433(d) under the Securities Act or any other document incident to such registration prepared by or on behalf of the Company or used or referred to by the Company;
(b) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (c) any violation or alleged violation by the indemnifying party (or any of
its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

“Deemed Liquidation Event” has the meaning set forth for such term in the Restated Certificate, whether or not the
holders of outstanding shares of Preferred Stock elect otherwise by written notice sent to the Company as provided in such definition. 

“Demand Notice” means notice sent by the Company to the Holders specifying that a demand registration has been
requested as provided in Section 3.1.1. 

  
 2 

 “Exchange Act” means the Securities Exchange Act of 1934, as
amended, and the rules and regulations promulgated thereunder. 
 “Excluded Registration” means (a) a
registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to an equity incentive, stock option, stock purchase, or similar plan; (b) a registration relating to an SEC Rule 145 transaction; (c) a
registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (d) a registration in which the only Common
Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

“FCPA” means the Foreign Corrupt Practices Act of 1977, as amended. 

“Form S-1” means such form under the Securities Act as in effect on the date
hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 
 “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial
information by reference to other documents filed by the Company with the SEC. 
 “Free Writing Prospectus” means a
free-writing prospectus, as defined in Rule 405. 
 “GAAP” means generally accepted accounting principles in the
United States. 
 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

“Immediate Family Member” means, with respect to any Person, such Person’s spouse or Spousal Equivalent, the
lineal descendant or antecedent, brother or sister, of such Person or such Person’s spouse or Spousal Equivalent, or the spouse or Spousal Equivalent, of any lineal descendant or antecedent, brother or sister of such Person, or such
Person’s spouse or Spousal Equivalent, whether or not any of the above are adopted. 
 “Initiating Holders”
means, collectively, Holders who properly initiate a registration request under this Agreement. 
 “IPO” means the
Company’s first underwritten public offering of its Common Stock under the Securities Act. 
 “Major Investor”
means any Investor that, individually or together with such Investor’s Affiliates, holds at least 1,000,000 shares of Registrable Securities. 

“New Securities” shall mean any Common Stock or Preferred Stock of the Company, whether now authorized or not, and
rights, options or warrants to purchase such Common Stock or Preferred Stock, and securities of any type whatsoever that are, or may become, convertible or exchangeable into such Common Stock or Preferred Stock; provided,
however, that the term “New Securities” does not include the Exempted Securities as defined in the Restated Certificate and shares of Series E Preferred Stock issued pursuant to the Series E Agreement, as amended from
time to time, subsequent to the date hereof. 

  
 3 

 “Notice” shall have the meaning set forth in Section 4.2. 

“Person” means any individual, corporation, partnership, trust, limited liability company, association or other
entity. 
 “Preferred Stock” means shares of the Company’s Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock. 

“Pro Rata Share” means, for each Major Investor, the ratio of (a) the number of shares of the Company’s
Common Stock issued or issuable upon conversion of the Shares owned by such Major Investor, to (b) a number of shares of Common Stock of the Company equal to the sum of (1) the total number of shares of Common Stock of the Company then
outstanding plus (2) the total number of shares of Common Stock of the Company into which all then outstanding shares of Preferred Stock of the Company are then convertible plus (3) the number of shares of Common Stock of the Company
reserved for issuance under any stock purchase and stock option plans of the Company and outstanding warrants. 
 “Registrable
Securities” means (a) the Common Stock issuable or issued upon conversion of Shares; and (b) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a
dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (a); excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable
rights under this Agreement are not assigned pursuant to Section 5.7, and excluding for purposes of Section 3 any shares for which registration rights have terminated pursuant to Section 5.14 of this Agreement. Notwithstanding the
foregoing, the Company shall in no event be obligated to register any Preferred Stock of the Company, and Holders of Registrable Securities will not be required to convert their Preferred Stock into Common Stock in order to exercise the registration
rights granted hereunder, until immediately before the closing of the offering to which the registration relates. 
 “Registrable
Securities then outstanding” means the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly)
pursuant to then exercisable and/or convertible securities that are Registrable Securities. 
 “Restated
Certificate” means the Company’s Restated Certificate of Incorporation (as may be amended from time to time). 

“Restricted Securities” means the securities of the Company required to bear the legend set forth in Section 3.12
hereof. 
 “SEC” means the Securities and Exchange Commission. 

“SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

  
 4 

 “SEC Rule 145” means Rule 145 promulgated by the SEC under the
Securities Act. 
 “SEC Rule 405” means Rule 405 promulgated by the SEC under the Securities Act. 

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to
the sale of Registrable Securities. 
 “Selling Holder Counsel” means one counsel for the selling Holders. 

“Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.00005. 

“Series A-1 Preferred Stock” means shares of the Company’s Series A-1 Preferred Stock, par value $0.00005. 
 “Series A-2
Preferred Stock” means shares of the Company’s Series A-2 Preferred Stock, par value $0.00005. 

“Series B Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value $0.00005. 

“Series C Preferred Stock” means shares of the Company’s Series C Preferred Stock, par value $0.00005. 

“Series D Preferred Stock” means shares of the Company’s Series D Preferred Stock, par value $0.00005. 

“Shares” means the shares of Company’s Preferred Stock, held from time to time by the Investors listed on Exhibit
A hereto and their permitted assigns. 
 “Spousal Equivalent” means an individual who is registered with any state
governmental entity as a domestic partner of the relevant person to whom such individual may be a Spousal Equivalent (a “Registered Domestic Partner”) or who (a) irrespective of whether or not the relevant person to whom such
individual may be a Spousal Equivalent and the Spousal Equivalent are the same sex, they are the sole spousal equivalent of the other for the last twelve (12) months, (b) they intend to remain so indefinitely, (c) neither are married to
anyone else nor a Registered Domestic Partner with anyone else, (d) both are at least 18 years of age and mentally competent to consent to contract, (e) they are not related by blood to a degree of closeness that which would prohibit legal
marriage in the state in which they legally reside, (f) they are jointly responsible for each other’s common welfare and financial obligations, and (g) they reside together in the same residence for the last twelve (12) months
and intend to do so indefinitely. 
 “Standoff Period” means the period commencing on the date of the final
prospectus relating to the IPO and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days or such longer period as may be required under applicable law). 

  
 5 

 2. COVENANTS OF THE COMPANY. 

2.1. Information Rights. 

2.1.1. Basic Financial Information. The Company will furnish to each Major Investor: (i) monthly unaudited financial statements for
each fiscal month of the Company, including an unaudited balance sheet as of the end of such fiscal month, an unaudited statement of operations and an unaudited statement of cash flows of the Company for such month, promptly upon request by such
Major Investor, (ii) quarterly unaudited financial statements for each fiscal quarter of the Company (except the last quarter of the Company’s fiscal year), including an unaudited balance sheet as of the end of such fiscal quarter, an
unaudited statement of operations and an unaudited statement of cash flows of the Company for such quarter, all prepared in accordance with GAAP, promptly and no later than thirty days after the end of the relevant quarter for which financial
statements are required to be submitted pursuant to this Section 2.1.1, (iii) annual unaudited financial statements for each fiscal year of the Company, including an unaudited balance sheet as of the end of such fiscal year, an unaudited
statement of operations and an unaudited statement of cash flows of the Company for such year, all prepared in accordance with GAAP, promptly and no later than thirty days after the end of the relevant year for which financial statements are
required to be submitted pursuant to this Section 2.1.1; provided, however, that upon approval of the Board such annual financial statements shall be audited and certified by independent public accountants of
nationally recognized standing selected by the Company; provided, further, that each of the financial statements provided pursuant to clauses (i), (ii) and (iii) above (x) may be subject to changes resulting from
normal year-end audit adjustments, (y) may not contain all notes thereto required in accordance with GAAP and (z) shall be accompanied with a comparison against the previously Board-approved
operating plan for such time period. If the Company has audited records of any of the foregoing, it shall provide those in lieu of the unaudited versions. 

2.1.2. Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any
purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Section 2 unless such confidential information (a) is known or becomes known to the public
in general (other than as a result of a breach of this Section 2.1.2 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has
been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose
confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any existing Affiliate,
partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, but only if such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality
of such information; or (iii) as may otherwise be required by law if the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 

  
 6 

 2.1.3. Inspection Rights. The Company shall permit each Major Investor to visit and
inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers, all at such reasonable times as may be requested by such Investor. 

2.1.4. Suspension or Termination. Notwithstanding anything in this Section 2 to the contrary but subject to Section 5.14, the
Company may cease providing the information set forth in this Section 2 for a limited period not to exceed ninety (90) days prior to the filing of a registration statement if it reasonably concludes it must do so to comply with the SEC
rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Section 2 shall be reinstated at such time as the Company is no longer actively employing its reasonable
efforts to cause such registration statement to become effective. 
 2.2. Employee Agreements. The Company will cause
each person now or hereafter employed or engaged by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) to enter into a form proprietary information and inventions agreement providing
(i) he, she or it is an at-will employee or a consultant of the Company, as the case may be, (ii) he, she or it will maintain all Company proprietary information in confidence, (iii) he, she or
it will assign all inventions created by him as an employee or consultant during his employment or service to the Company, and (iv) he, she or it will not disclose any information related to the Company’s work force and will not solicit
any employees or consultant from the Company for a period of time of twelve months, beginning on the last day of on which such individual provided services to the Company. 

2.3. Employee Vesting. Unless otherwise approved by the Board, all employees, directors, consultants and other service
providers of the Company or its subsidiaries who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as
applicable, providing for vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service (or the date of grant in the case of a
grant to an existing employee or consultant), and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months. In addition, unless otherwise approved by the Board,
the Company shall retain the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock. 

2.4. Insurance. The Company shall use its commercially reasonable efforts to cause its Directors and Officers liability
insurance policies to be maintained until such time as the Board determines that such insurance should be discontinued. 
 2.5. Board
Matters. The Company shall reimburse the nonemployee directors for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s
travel policy) in connection with attending meetings of the Board of Directors. 
 2.6. Green Dot. The Company shall not enter
into any banking or nonbanking transaction with Green Dot Corporation or any of its subsidiaries (Next Estate Communications and Bonneville Bancorp) without the prior written consent of Sequoia Capital U.S. Growth Fund VI, L.P., or its Affiliates.

  
 7 

 2.7. FCPA Matters. The Company represents that it shall not — and shall
not permit any of its subsidiaries or Affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to — promise, authorize or make any payment to, or otherwise
contribute any item of value, directly or indirectly, to any third party, including any Non-U.S. Official, in each case, in violation of the FCPA, the Bribery Act 2010 (“U.K. Bribery
Act”), or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall — and shall cause each of its Subsidiaries and Affiliates to — cease all of its or their respective activities,
as well as remediate any actions taken by the Company, its Subsidiaries or Affiliates, or any of their respective directors, officers, managers, employees, independent contractors, representatives or agents in violation of the FCPA, the U.K. Bribery
Act, or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall — and shall cause each of its subsidiaries and Affiliates to — maintain systems of internal controls (including, but not limited
to, accounting systems, purchasing systems and billing systems) to ensure compliance with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. 

2.8. Investor Provisions. Each party hereto hereby agrees, for the benefit of Nikon Corporation or one of its controlled
entities (together, “Nikon”), that such party shall hold, and shall use its reasonable best efforts to cause its representatives to hold, in confidence, unless compelled to disclose by judicial or administrative process or by
other requirements of applicable law or permitted to disclose with Nikon’s prior written consent, all confidential documents and information concerning Nikon and its Affiliates and the transactions contemplated by the Series E Agreement,
including the identity of Nikon and the existence and terms of each of the Transaction Agreements (as defined in the Series E Agreement), except to the extent that such information is (a) in the public domain through no fault of such party and
its Affiliates, in each case not in violation of this Agreement or another contractual or fiduciary obligation, (b) later lawfully acquired by such party from sources other than those related to the Transaction Agreements and not subject to a
confidentiality obligation in respect of such information, or (c) was already known by such party, without confidentiality restrictions, at the time of disclosure, as shown by such party’s files and records immediately prior to the time of
disclosure. Furthermore, the Company and the Investors hereby acknowledge that Nikon may be engaged in, or invested in, businesses that could be perceived to be directly or indirectly competitive with the Company’s current or future operations
and commercial relationships. Nikon shall not be liable to the Company or any other Investors for any claim arising out of, or based upon, (i) any and all of Nikon’s commercial actions which could be perceived to be, or potentially are,
directly or indirectly competitive to the Company’s current or future commercial relationships, (ii) any and all collaborations, partnerships, or investments by Nikon with any entity which could be perceived to be, or potentially are,
directly or competitive to the Company, or (iii) any and all actions taken by any officer or other representative of Nikon to assist any such actions under (i) or (ii); provided, however, that nothing herein shall relieve (x) Nikon
from liability associated with the unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement or (y) any director or officer of the Company from any liability associated with his or her fiduciary
duties to the Company. 
 2.9. Right to Conduct Activities. The Company and the Investors hereby acknowledge that each of
Black Diamond Ventures XXII, LLC and its Affiliates (“BDV”), Paxion Capital, L.P. (“Paxion”), Sequoia Capital, L.P. and its Affiliates (“Sequoia”) and Walden Riverwood Ventures,

  
 8 

 
L.P. and its Affiliates (“Walden”) is a professional investment fund, and as such invests in numerous portfolio companies, some of which may be deemed competitive with the
Company’s business. None of BDV, Paxion, Sequoia or Walden shall be liable to the Company for any claim arising out of, or based upon, (i) the investment by BDV, Paxion, Sequoia or Walden, as applicable, in any entity competitive to the
Company, or (ii) actions taken by any partner, officer or other representative of BDV, Paxion, Sequoia or Walden, as applicable, to assist any such competitive company, whether or not such action was taken as a board member of such competitive
company or otherwise; provided, however, that nothing herein shall relieve (x) BDV, Paxion, Sequoia or Walden or any other party from liability associated with the unauthorized disclosure of the Company’s confidential
information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. 

3. REGISTRATION RIGHTS. 
 3.1.
Demand Registration. 
 3.1.1. Form S-1 Demand. If at any time after the earlier
of (a) six (6) years after the date of this Agreement or (b) one hundred eighty (180) days after the effective date of the registration statement for the Company’s IPO, the Company receives a request from Holders of a majority of
the Registrable Securities then outstanding that the Company file a Form S-1 registration statement with respect to any Registrable Securities then outstanding (and the Registrable Securities subject to such
request have an anticipated aggregate offering price of at least $25,000,000), then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating
Holders; and (ii) use its reasonable best efforts to as soon as practicable, and in any event within ninety (90) days after the date such request is given by the Initiating Holders, file a Form S-1
registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders,
as specified by notice given by each such Holder to the Company within twenty (20) days after the date the Demand Notice is given, and in each case, subject to the limitations of Section 3.1.3 and Section 3.2. 

3.1.2. Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from any Holder of the Registrable Securities then outstanding that the Company file a Form S-3 registration
statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price of at least $5,000,000, then the Company shall (a) within ten (10) days after the date such request is given, give
a Demand Notice to all Holders other than the Initiating Holders; and (b) use reasonable best efforts to as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders,
file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such
Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Section 3.1.2 and Section 3.3. 

  
 9 

 3.1.3. Delay. Notwithstanding the foregoing obligations, if the Company furnishes to
Holders requesting a registration pursuant to this Section 3 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board it would be materially detrimental to the Company and its
stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (a) materially interfere with a
significant acquisition, corporate reorganization, or other similar transaction involving the Company; (b) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or
(c) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or
effectiveness thereof shall be tolled correspondingly, for a period of not more than one hundred twenty (120) days after the request of the Initiating Holders is given; provided, however, that (i) the
Company may not invoke this right more than once in any twelve (12) month period and (ii) the Company shall not register any securities for its own account or that of any other stockholder during such one hundred twenty (120) day
period other than an Excluded Registration. 
 3.1.4. Limitations. 

(a). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 3.1.1: (i)
during the period that is ninety (90) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date of, a Company-initiated registration,
provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two (2) registrations pursuant to
Section 3.1.1; or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to
Section 3.1.1. 
 (b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to
Section 3.1.2: (i) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated
registration, provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if, with respect to request from the Holders pursuant
to Section 3.1.2(a) the Company has effected two (2) registrations pursuant to Section 3.1.2 within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as
“effected” for purposes of this Section 3.1.4 until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to
pay the registration expenses therefor, and forfeit their right to one registration on Form S-1 or S-3, as applicable, pursuant to Section 3.5, in which case such
withdrawn registration statement shall be counted as “effected” for purposes of this Section 3.1.4; provided, that if such withdrawal is during a period the Company has deferred taking action pursuant to Subsection
3.1.3, then the Initiating Holders may withdraw their request for registration and such registration will not be counted as “effected” for purposes of this Subsection 3.1.4. 

  
 10 

 3.2. Company Registration. If the Company proposes to register
(including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in
an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall,
subject to the provisions of Section 3.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any
registration initiated by it under this Section 3.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such
withdrawn registration shall be borne by the Company in accordance with Section 3.6. 
 3.3. Underwriting
Requirements. 
 3.3.1. Inclusion. If, pursuant to Section 3.1, the Initiating Holders intend to distribute the
Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 3.1, and the Company shall include such information in the Demand Notice. The
underwriter(s) will be selected by the Company, subject only to the reasonable approval of the holders of at least 60% of Registrable Securities held by the Initiating Holders. In such event, the right of any Holder to include such Holder’s
Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided
in Section 3.4.5) enter into an underwriting agreement with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Section 3.3, if the managing underwriter(s) advise(s) the Initiating Holders in
writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of
Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned
or held by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities owned or held by the Holders to be included in
such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the
number of shares allocated to any Holder to the nearest one hundred (100) shares. 
 3.3.2. Underwriter Cutback. In connection
with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Section 3.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the
Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters. If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number
of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of
such securities, including Registrable Securities, which the underwriters and the 

  
 11 

 
Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be
registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable) to the number of Registrable Securities owned or
held by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number
of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (a) the number of Registrable Securities included in the offering be reduced unless all other securities (other
than securities to be sold by the Company) are first entirely excluded from the offering, (b) the number of Registrable Securities included in the offering be reduced below 25% of the total number of securities included in such offering, unless
such offering is the IPO, in which case the selling Holders may be excluded entirely if the underwriters make the determination described above and no other stockholder’s securities are included in such offering or (c) notwithstanding
clause (b) above, any Registrable Securities held by the Investors be excluded from such underwriting unless all Key Holder Registrable Securities are first excluded from such offering. For purposes of the provision in this Section 3.3.2
concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate
Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to
such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned or held by all Persons included in such “selling Holder,” as defined in this sentence. 

3.3.3. Registration Not Effected. For purposes of Section 3.1, a registration shall not be counted as “effected” if, as
a result of an exercise of the underwriter’s cutback provisions in Section 3.3.1, fewer than twenty-five percent (25%) of the total number of Registrable Securities that Holders have requested to be included in such registration statement
are actually included. 
 3.4. Obligations of the Company. Whenever required under this Section 3 to effect the
registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 3.4.1. prepare and file with the
SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective as promptly as practicable, and, upon the request of the Holders of a
majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has
been completed; provided, however, that (i) such 120-day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an
underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3
that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such 120-day period shall be extended for up to sixty (60) days, if necessary, to keep
the registration statement effective until all such Registrable Securities are sold; 

  
 12 

 3.4.2. prepare and file with the SEC such amendments and supplements to such registration
statement, the prospectus and, if required, any Free Writing Prospectus used in connection with such registration statement as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such
registration statement; 
 3.4.3. furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus
and any Free Writing Prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

3.4.4. use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a
general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

3.4.5. in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 3.4.6. use its reasonable efforts to cause all such Registrable Securities
covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

3.4.7. provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number
for all such Registrable Securities, in each case not later than the effective date of such registration; 
 3.4.8. promptly make available
for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling
Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

3.4.9. notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus or Free Writing Prospectus forming a part of such registration statement has been filed; 

3.4.10. after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or
supplement such registration statement or prospectus or Free Writing Prospectus; 

  
 13 

 3.4.11. use its commercially reasonable efforts to obtain for the underwriters one or more
“cold comfort” letters, dated the effective date of the related registration statement (and, if such registration includes an underwritten public offering, dated the date of the closing under the underwriting agreement), signed by the
Company’s independent public accountants in customary form and covering such matters of the type customarily covered by “cold comfort” letters; 

3.4.12. use its commercially reasonable efforts to obtain for the underwriters on the date such securities are delivered to the underwriters
for sale pursuant to such registration a legal opinion of the Company’s outside counsel with respect to the registration statement, each amendment and supplement thereto, the prospectus included therein (including the preliminary prospectus)
and such other documents relating thereto in customary form and covering such matters of the type customarily covered by legal opinions of such nature; 

3.4.13. to the extent the Company is a well-known seasoned issuer (as defined in SEC Rule 405 at the time any request for registration is
submitted to the Company in accordance with Section 3.1, if so requested, file an Automatic Shelf Registration Statement to effect such registration; and 

3.4.14. if at any time when the Company is required to re-evaluate its well-known seasoned issuer
status for purposes of an outstanding Automatic Shelf Registration Statement used to effect a request for registration in accordance with Section 3.1.2 the Company determines that it is not a well-known seasoned issuer and (i) the
registration statement is required to be kept effective in accordance with this Agreement and (ii) the registration rights of the applicable Holders have not terminated, use commercially reasonable efforts to promptly amend the registration
statement on a form the Company is then eligible to use or file a new registration statement on such form, and keep such registration statement effective in accordance with the requirements otherwise applicable under this Agreement. 

3.5. Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant
to this Section 3 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of
such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 
 3.6. Expenses of
Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 3, including all registration, filing, and qualification fees; printers’ and
accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements of one Selling Holder Counsel, not to exceed $30,000 per transaction, shall be borne and paid by the Company; provided, however,
that (a) the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 3.1 if the registration request is subsequently withdrawn at the request of the Holders of at least 60% of the
Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of at least 60%
of the Registrable Securities agree to forfeit their right to one registration pursuant to Section 3.1.1 or Section 3.1.2, as the case may be, and (b) if, at the time of such withdrawal, the Holders

  
 14 

 
shall have learned of a material adverse change in the condition, business, or prospects of the Company not known to the Holders at the time of their request and have withdrawn the request with
reasonable promptness after learning of such information, then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Section 3.1.1 or Section 3.1.2. All Selling
Expenses relating to Registrable Securities registered pursuant to this Section 3 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

3.7. Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise
delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 3. 

3.8. Indemnification. If any Registrable Securities are included in a registration statement under this Section 3:

 3.8.1. Company Indemnification. To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder,
and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls
such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses
reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement
contained in this Section 3.8.1 shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, conditioned, or
delayed nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder,
underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. 
 3.8.2. Selling
Holder Indemnification. To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each
Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration
statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with
written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses
reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that (a) the indemnity
agreement contained in this Section 3.8.1 shall not apply to amounts paid in settlement of any 

  
 15 

 
such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld, conditioned or delayed, and (b) that in no event
shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Sections 3.8.2 and 3.8.4 exceed the net proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the
case of each Holder, in the event of fraud or willful misconduct solely by such Holder. 
 3.8.3. Procedures. Promptly after receipt
by an indemnified party under this Section 3.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect
thereof is to be made against any indemnifying party under this Section 3.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the
indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided,
however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by
the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party
represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under
this Section 3.8, solely to the extent that such failure prejudices the indemnifying party’s ability to defend such action. 

3.8.4. Contribution. To provide for just and equitable contribution to joint liability under the Securities Act in any case in which
either (a) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 3.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent
jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Section 3.8 provides for indemnification in such case,
or (b) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Section 3.8, then, and in each such case, such parties will contribute to the aggregate losses,
claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with
the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified
party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or
by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that: 

(a). in any such case, (A) no Holder will be required to contribute any amount in excess of the public offering price of all such
Registrable Securities offered and sold by 

  
 16 

 
such Holder pursuant to such registration statement, and (B) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be
entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and 
 (b). in no event shall a
Holder’s liability pursuant to this Section 3.8.4, when combined with the amounts paid or payable by such Holder pursuant to Section 3.8.2, exceed the proceeds from the offering received by such Holder (net of any Selling Expenses)
paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 
 3.8.5. Underwriting Agreement Controls.
Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing
provisions, the provisions in the underwriting agreement shall control. 
 3.8.6. Survival. Unless otherwise superseded by an
underwriting agreement entered into in connection with the underwritten public offering, the obligations of the Company and Holders under this Section 3.8 shall survive the completion of any offering of Registrable Securities in a registration
under this Section 3, and otherwise shall survive the termination of this Agreement. 
 3.9. Reports under the Exchange Act.
With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a
registration on Form S-3, the Company shall: 
 3.9.1. use commercially reasonable efforts to make
and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

3.9.2. use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company
under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

3.9.3. furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a
written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities
Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any
time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time
after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

3.10. Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without
the prior written consent of the Holders of at least 

  
 17 

 
60% of the Registrable Securities then outstanding enter into any agreement with any holder or prospective holder of any securities of the Company that would allow such holder or prospective
holder to include such securities in any registration if such agreement (a) would allow such holder or prospective holder to include a portion of its securities in any “piggyback” registration if such inclusion could reduce the number
of Registrable Securities that selling Holders could be entitled to include in such registration under Sections 3.2 and 3.3.2 hereof or (b) would allow such holder or prospective holder to initiate a demand for registration of any of its securities
at a time earlier than the Holders of Registrable Securities can demand registration under Section 3.1 hereof. 
 3.11.
“Market Stand-off” Agreement. Each Holder hereby agrees that, during the Standoff Period, such Holder will not, without the prior written consent of the Company or the managing
underwriter, 
 3.11.1. lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right, or warrant to purchase or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock, or any securities convertible into or exercisable or exchangeable (directly or indirectly) for
Common Stock, held immediately before the effective date of the registration statement for such offering; or 
 3.11.2. enter into any swap
or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (a) or (b) above is to be settled by delivery of Common
Stock or other securities, in cash, or otherwise. 
 The foregoing provisions of this Section 3.11 shall apply only to the IPO and shall not apply to
the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall be applicable to the Holders only if all officers, directors, and stockholders individually owning more than one percent (1%) of the Company’s outstanding
Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock) are similarly bound. For purposes of this Section 3.11, the term “Company” shall include any wholly-owned subsidiary of the Company
into which the Company merges or consolidates. Subject to customary shareholding thresholds and exceptions, any discretionary waiver or termination of the restrictions of any or all such agreements by the Company or the underwriters shall apply pro
rata to all Holders subject to such agreements, based on the number of shares subject to such agreements. In order to enforce the foregoing covenant, the Company shall have the right to place restrictive legends on the certificates representing the
shares subject to this Section 3.11 and to impose stop transfer instructions with respect to such shares until the end of such period. The underwriters in connection with such registration are intended third-party beneficiaries of this
Section 3.11 and shall have the right, power, and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in
connection with such registration that are consistent with this Section 3.11 or that are necessary to give further effect thereto. 

  
 18 

 3.12. Restrictions on Transfer. 

3.12.1. Agreement Binding. The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and
the Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure
compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities
subject to the provisions and upon the conditions specified in this Agreement. 
 3.12.2. Legends. Each certificate or instrument
representing (a) the Preferred Stock, (b) the Registrable Securities, and (c) any other securities issued in respect of the securities referenced in clauses (a) and (b), upon any stock split, stock dividend, recapitalization,
merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of Section 3.12.3) be stamped or otherwise imprinted with a legend substantially in the following form: 

THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR
INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM REASONABLY SATISFACTORY TO THE
COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
 THE SHARES REPRESENTED BY THIS
CERTIFICATE MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 

The Holders consent to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to
implement the restrictions on transfer set forth in this Section 3.12. 
 3.12.3. Procedure. The holder of each certificate
representing Restricted Securities, by acceptance thereof, agrees to comply in all respects with the provisions of this Section 3. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a
registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the
manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (a) a written opinion of legal counsel who shall,
and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the 

  
 19 

 
Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (b) a “no action” letter from the SEC to the effect that the
proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (c) any other evidence reasonably satisfactory to
counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to
sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (i) in any transaction in
compliance with SEC Rule 144 or (ii) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided, that each transferee agrees in writing to be subject to
the terms of this Section 3.12. Each certificate or instrument evidencing the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth
in Section 3.12.2, except that such certificate shall not bear such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the
Securities Act. Until the IPO, no Holder shall transfer any Restricted Securities to any person or entity that is determined to be a competitor of the Company, in the good faith judgment of the Board. 

4. PARTICIPATION RIGHT. 

4.1. General. Each Major Investor has the right of first refusal to purchase such Major Investor’s Pro Rata Share of all
(or any part) of any New Securities that the Company may from time to time issue after the date of this Agreement, provided, however, such Major Investor shall have no right to purchase any such New Securities if such
Major Investor cannot demonstrate to the Company’s reasonable satisfaction that such Major Investor is at the time of the proposed issuance of such New Securities an “accredited investor” as such term is defined in Regulation D under
the Securities Act. 
 4.2. Procedures. In the event that the Company proposes to undertake an issuance of New Securities, it
shall give to each Major Investor a written notice of its intention to issue New Securities (the “Notice”), describing the type of New Securities and the price and the general terms upon which the Company proposes to issue
such New Securities given in accordance with Section 6.2. Each Major Investor shall have ten (10) days from the date such Notice is effective, as determined pursuant to Section 6.2 based upon the manner or method of notice, to agree
in writing to purchase such Major Investor’s Pro Rata Share of such New Securities for the price and upon the general terms specified in the Notice by giving written notice (an “Investor Notice”) to the Company and
stating therein the quantity of New Securities to be purchased (not to exceed such Major Investor’s Pro Rata Share, except as set forth in the following sentence). In addition, each Major Investor that elects to purchase or acquire all of its
Pro Rata Share of such New Securities (each, a “Fully Exercising Investor”) may, in the Investor Notice, elect to purchase or acquire, in addition to its Pro Rata Share, a portion of the New Securities, if any, for which
other Major Investors were entitled to subscribe but that are not subscribed for by such Major Investors. The amount of such overallotment that each Fully Exercising Investor shall be entitled to purchase is equal to the proportion that the number
of shares of the Common Stock 

  
 20 

 
issued or issuable upon conversion of the Shares owned by such Fully Exercising Investor bears to the Common Stock issued or issuable upon conversion of the Shares owned by all Fully Exercising
Investors who wish to purchase such unsubscribed shares. A Major Investor’s election may be conditioned on the consummation of the transaction described in the Notice. 

4.3. Failure to Exercise. In the event that the Major Investors fail to exercise in full the right of first refusal within such
ten (10) day period, then the Company shall have sixty (60) days thereafter to sell the New Securities with respect to which the Major Investors’ rights of first refusal hereunder were not exercised, at a price and upon general terms
not materially more favorable to the purchasers thereof than specified in the Company’s Notice to the Major Investors. In the event that the Company has not issued and sold the New Securities within such sixty (60) day period, then the
Company shall not thereafter issue or sell any New Securities without again first offering such New Securities to the Major Investors pursuant to this Section 4. 

4.4. Alternate Procedure. Notwithstanding any provision hereof to the contrary, in lieu of complying with the provisions of
Sections 4.1 and 4.2, the Company may elect to give notice to the Major Investors within thirty (30) days after the issuance of New Securities. Such notice shall describe the type, price, and terms of the New Securities, and the identities of
the Persons to whom the New Securities were sold. Each Major Investor shall have twenty (20) days after the date the Company’s notice is given to elect, by giving notice to the Company, to purchase up to the number of New Securities that
such Major Investor would otherwise have the right to purchase pursuant to Section 4.2 above had the Company complied with the provisions of Sections 4.1 and 4.2 in connection with the issuance of such New Securities under the terms and
conditions set forth in the Company’s notice pursuant to this Section 4.4. Any Major Investor electing to purchase such New Securities shall also have rights of oversubscription to purchase New Securities that were purchasable by other
Major Investors pursuant to the foregoing sentence but were not so purchased, and such rights of oversubscription shall be apportioned in a manner consistent with the apportionment among Fully Exercising Investors described in Section 4.2. The
closing of such sale shall occur within sixty (60) days of the date notice is given to the Major Investors. 
 5. GENERAL
PROVISIONS. 
 5.1. Amendment and Waiver of Rights. Any provision of this Agreement may be amended and the observance
thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and (a) with respect to Section 2 and 4 and any other provision of this Agreement
to the extent such provision pertains to Sections 2 or 4, the holders of at least 60% of the Registrable Securities then outstanding and held by the Major Investors or (b) with respect to any other provision of this Agreement, the holders of at
least 60% of the shares of Common Stock issued or issuable upon conversion of the then outstanding shares of Preferred Stock held by the Investors (voting as a single class and on an as-converted basis);
provided that (i) the Company may in its sole discretion waive compliance with Section 3.12.3 (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of
Section 3.12.3 shall be deemed to be a waiver); (ii) any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party; (iii) the Company may, without the consent or approval of
any other party hereto, cause additional persons who purchase shares of Series E Preferred Stock after the date hereof pursuant to the Series E Agreement to become party to this Agreement as Investors and amend Exhibit A hereto accordingly;
and (iv) that if an amendment 

  
 21 

 
or waiver alters or changes the rights or obligations of an Investor under this Agreement so as to affect such Investor adversely, but does not so affect all Investors as a group, then such
amendment or waiver shall not be binding on the adversely-affected Investor without its separate written consent. Any amendment or waiver effected in accordance with this Section 5.1 shall be binding upon each Investor, each Holder, each
permitted successor or assignee of such Investor or Holder and the Company. Notwithstanding the foregoing, Section 4 may not be amended, modified or terminated and the observance of any term thereof may not be waived with respect to any
Major Investor without the written consent of such Major Investor, unless such amendment or waiver applies to all Major Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular
transaction shall be deemed to apply to all Major Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Major Investors may nonetheless, by agreement with the Company, purchase securities in such
transaction); provided, that notwithstanding any waiver of the observance of any term of Section 4, in the event that (x) the provisions of Section 4 are waived by the Major Investors in accordance with this Section 5.1 in
respect of a particular transaction, and (y) one or more Major Investors purchase securities in such transaction (the amount of such securities available to be purchased by any Major Investors, the “Post-Waiver MI
Securities” and such participating Major Investors the “Post-Waiver Major Investors”), then each other Major Investor shall have the right to purchase all (or any part) of such Major Investor’s Pro Rata
Share of the Post-Waiver MI Securities, in accordance with and subject to the provisions of Section 4 (including without limitation the notice and election periods set forth therein) as if such Post-Waiver MI Securities were “New
Securities” under Section 4, or, if greater, such number of Post-Waiver MI Securities as represents the same proportion of such Major Investor’s Pro Rata Share as the greatest proportion of Post-Waiver MI Securities being purchased by
the Post-Waiver Major Investor represents of such Post-Waiver Major Investor’s Pro Rata Share. By way of example only, if a Post-Waiver Major Investor is purchasing 50% of its Pro Rata Share, then each other Major Investor shall have the right
to purchase at least 50% of such Major Investor’s Pro Rata Share. If there are insufficient Post-Waiver MI Securities available, then each Major Investor shall be allocated Post-Waiver MI Securities based upon its relative Pro Rata Share (as
measured against all other Major Investors purchasing Post-Waiver MI Securities). 
 5.2. Notices. All notices and other
communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or: (a) personal delivery to the party to be notified, (b) when sent, if sent by facsimile
or electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next business day, (c) five (5) days after having been sent by registered or certified mail, return
receipt requested, postage prepaid, or (d) one (1) business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt. All communications shall
be sent to the respective parties at their address as set forth on the signature page or Exhibit A or Exhibit B hereto, or to such address or facsimile number as subsequently modified by written notice given in accordance with this Section 5.2.
If notice is given to the Company, it shall be sent to5858 Horton Street, Suite 320, Emeryville, CA 94608, Attention: Chief Executive Officer; and a copy (which shall not constitute notice) shall also be sent to Latham & Watkins LLP, 140
Scott Drive, Menlo Park, California 94025 Attn: Brian J. Cuneo. 

  
 22 

 Subject to the limitations set forth in Delaware General Corporation Law §232(e), each Investor
consents to the delivery of any notice to stockholders given by the Company under the Delaware General Corporation Law or the Company’s certificate of incorporation or bylaws by (i) facsimile telecommunication to the facsimile number set
forth in the exhibit to this Agreement (or to any other facsimile number for such Investor in the Company’s records), or (ii) electronic mail to the electronic mail address set forth in the exhibit to this Agreement (or to any other
electronic mail address for the Investor in the Company’s records). This consent may be revoked by an Investor by written notice to the Company and may be deemed revoked in the circumstances specified in Delaware General Corporation Law
§232. 
 5.3. Entire Agreement. This Agreement and the documents referred to herein, together with all the Exhibits
hereto, constitute the entire agreement and understanding of the parties with respect to the subject matter of this Agreement, and supersede any and all prior understandings and agreements, including but not limited to the Prior Agreement, whether
oral or written, between or among the parties hereto with respect to the specific subject matter hereof. 
 5.4. Governing
Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of California, regardless of the laws that might otherwise govern under applicable principles of conflicts of law. 

5.5. Severability The invalidity or unenforceability of any provision hereof shall in no way affect the validity or
enforceability of any other provision. 
 5.6. Third Parties. Nothing in this Agreement, express or implied, is intended to
confer upon any person, other than the parties hereto and their successors and assigns, any rights or remedies under or by reason of this Agreement. 

5.7. Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder
to a transferee of Registrable Securities that (a) is an Affiliate, partner, member, limited partner, retired or former partner, retired or former member, or stockholder of a Holder or such Holder’s Affiliate; (b) is a Holder’s
Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; (c) after such transfer, holds at least one percent (1%) of the shares of Registrable Securities (or if the
transferring Holder owns less than one percent (1%) of the Registrable Securities, then all Registrable Securities held by the transferring Holder); or (d) is a venture capital fund that is controlled by or under common control with one or more
general partners or managing partners or managing members of, or shares the same management company with, the Holder; provided, however, that (i) the Company is, within a reasonable time after such transfer,
furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (ii) such transferee agrees in a written instrument delivered to the Company to
be bound by and subject to the terms and conditions of this Agreement. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (A) that is an Affiliate, limited partner,
retired or former partner, member, retired or former member, or stockholder of a Holder or such Holder’s Affiliate; (B) who is a Holder’s Immediate Family Member; or (C) that is a trust for the benefit of an individual Holder or
such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder. The terms and conditions of this Agreement inure to the 

  
 23 

 
benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than
the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

5.8. Titles and Headings. The titles, captions and headings of this Agreement are included for ease of reference only and will
be disregarded in interpreting or construing this Agreement. Unless otherwise specifically stated, all references herein to “sections” and “exhibits” will mean “sections” and “exhibits” to this Agreement. 

5.9. Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered
will be deemed an original, and all of which together shall constitute one and the same agreement. 
 5.10. Costs and Attorneys’
Fees. In the event that any action, suit or other proceeding is instituted concerning or arising out of this Agreement or any transaction contemplated hereunder, the prevailing party shall recover all of such party’s costs and
attorneys’ fees incurred in each such action, suit or other proceeding, including any and all appeals or petitions therefrom. 
 5.11.
Adjustments for Stock Splits, Etc. Wherever in this Agreement there is a reference to a specific number of shares of Common Stock or Preferred Stock of the Company of any class or series, then, upon the occurrence of any subdivision,
combination or stock dividend of such class or series of stock, the specific number of shares so referenced in this Agreement shall automatically be proportionally adjusted to reflect the effect on the outstanding shares of such class or series of
stock by such subdivision, combination or stock dividend. 
 5.12. Further Assurances. The parties agree to execute such
further documents and instruments and to take such further actions as may be reasonably necessary to carry out the purposes and intent of this Agreement. 

5.13. Facsimile Signatures. This Agreement may be executed and delivered by facsimile or electronically and upon such delivery
the facsimile or PDF signature will be deemed to have the same effect as if the original signature had been delivered to the other party. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature
complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

5.14. Termination. 

5.14.1. Generally. Except as set forth below, the rights, duties and obligations in the Agreement (other than Section 2.1.2, which
shall survive indefinitely) shall terminate upon the earliest to occur of (a) immediately prior to the closing of the IPO, (b) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of
the Exchange Act, or (c) a Deemed Liquidation Event. 
 5.14.2. Registration Rights. The right of any Holder to request
registration or inclusion of Registrable Securities in any registration pursuant to Section 3.1.1 or 3.1.2 shall 

  
 24 

 
terminate upon the earliest to occur of: (a) when such Holder holds less than one percent (1%) of the Company’s outstanding Common Stock and all such Holder’s Registrable
Securities (together with the Registrable Securities held by any Affiliate of the Holder with whom such Holder must aggregate its sales under Rule 144) could be sold without any restriction on volume or manner of sale in any three-month period under
SEC Rule 144 or any successor; (b) upon a Deemed Liquidation Event; or (c) the fifth (5th) anniversary of the IPO. 
 5.15.
Dispute Resolution. Each party (a) hereby irrevocably and unconditionally submits to the jurisdiction of the federal or state courts located in the Northern District of California for the purpose of any suit, action or other
proceeding arising out of or based upon this Agreement or the Transaction Agreements (as defined in the Series B Agreement), (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement or the
Transaction Agreements except in the federal or state courts located in the Northern District of California, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding,
any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of
the suit, action or proceeding is improper or that this Agreement, the Transaction Agreements or the subject matter hereof and thereof may not be enforced in or by such court. 

5.16. Acknowledgment. The Company acknowledges that the Investors are in the business of venture capital investing and
therefore review the business plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company. Nothing in this Agreement shall
preclude or in any way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company. 

5.17. Additional Investors. If the Company issues additional shares of Series E Preferred Stock after the date hereof, as a
condition to the issuance of such shares the Company shall require that any purchaser of any shares of Series E Preferred Stock become a party to this Agreement by executing and delivering a counterpart signature page hereto agreeing to be bound by
and subject to the terms of this Agreement as an Investor hereunder. Each such person thereafter shall be deemed an Investor for all purposes under this Agreement. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 25 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
  

			
	COMPANY:
	
	BERKELEY LIGHTS, INC.
		
	By:	 	/s/ Eric Hobbs
	Name:	 	Eric Hobbs
	Title:	 	Chief Executive Officer

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and
Restated Investors’ Rights Agreement as of the date and year first written above. 
 INVESTOR: 

NIKON CORPORATION 
  

			
		
	By:	 	/s/ Masato Hamatani
	Name:	 	Masato Hamatani
	Title:	 	General Manager, Healthcare Business Unit

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 
 THE
KHANDROS-BLOCH REVOCABLE 
 TRUST U/A/D 1/24/1997 
  

			
		
	By:	 	/s/ Igor Khandros
	Name:	 	Igor Khandros
	Title:	 	Trustee

 THE KHANDROS 1997 TRUST I 
  

			
		
	By:	 	/s/ Igor Khandros
	Name:	 	Igor Khandros
	Title:	 	Trustee

 THE KHANDROS 1997 TRUST II 
  

			
		
	By:	 	/s/ Igor Khandros
	Name:	 	Igor Khandros
	Title:	 	Trustee

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 

SEQUOIA CAPITAL U.S. VENTURE FUND XV, L.P. 
 SEQUOIA
CAPITAL U.S. VENTURE XV PRINCIPALS FUND, L.P. 
 SEQUOIA CAPITAL U.S. VENTURE PARTNERS FUND XV, L.P. 

SEQUOIA CAPITAL U.S. VENTURE PARTNERS FUND XV (Q), L.P.., 

all Cayman Islands exempted limited partnerships 
  

			
	 By:
	  	 SC U.S. VENTURE XV MANAGEMENT L.P.

		  	 a Cayman Islands exempted limited partnership, General Partner of Each

  

			
	 By:
	  	 SC US (TTGP), LTD.,

		  	 a Cayman Islands exempted company, its General Partner

  

			
		
	By:	 	/s/ Michael Moritz
	Name:	 	Michael Moritz
	Title:	 	 Authorized Signatory

 SEQUOIA CAPITAL U.S. GROWTH FUND VI, L.P. 

SEQUOIA CAPITAL U.S. GROWTH VI PRINCIPALS FUND, L.P. 
 All
Cayman Islands exempted limited partnerships 
  

			
	 By:
	  	 SC U.S. Growth VI Management, L.P.

		  	 A Cayman Islands exempted limited partnership

		  	 General Partner of each

  

			
	 By:
	  	 SC US (TTGP) LTD.,

		  	 A Cayman Islands exempted company, its General Partner

  

			
		
	By:	 	/s/ Michael Moritz
	Name:	 	Michael Moritz
	Title:	 	 Authorized Signatory

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 

PAXION CAPITAL, LP 
  

			
	By:	 	Paxion Partners, LP
		
	By:	 	/s/ Duncan Robertson
	Name:	 	Duncan Robertson
	Title:	 	 Chief Financial Officer

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 
 THE
DAVIDOW FAMILY TRUST 
  

			
		
	By:	 	/s/ Bill Davidow
	Name:	 	Bill Davidow
	Title:	 	Trustee

 BILL’S TRUST U/A LEONARD S. DAVIDOW 
  

			
		
	By:	 	/s/ Bill Davidow
	Name:	 	Bill Davidow
	Title:	 	Trustee

 DAVIDOW DESCENDANTS TRUST 
  

			
		
	By:	 	/s/ Bill Davidow
	Name:	 	Bill Davidow
	Title:	 	Trustee

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 

LUCAS VENTURE GROUP XXII, LLC 
  

			
	By:	 	 LVG GP IV, LLC

		 	 Its Managing Member

		
	By:	 	/s/ Donald A. Lucas
	Name:	 	Donald A. Lucas
	Title:	 	 Authorized Signatory

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 
 SST
HOLDINGS, INCORPORATED 
  

			
		
	By:	 	/s/Karen Higgins
	Name:	 	
	Title:	 	

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 

PRESTRIDGE 1989 FAMILY TRUST 
  

			
		
	By:	 	/s/ James A. Prestridge
	Name:	 	James A Prestridge
	Title:	 	Trustee

 LONE TREE WY, LLC 
  

			
		
	By:	 	/s/ James A. Prestridge
	Name:	 	James A Prestridge
	Title:	 	Administrative Member

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 

FKS INVESTMENTS VIII, LLC 
  

			
		
	 By:
	 	 /s/ Richard Hoffman

	 Name:
	 	 Richard Hoffman

	 Title:
	 	 Manager

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 

LESLIE FAMILY TRUST U/A/ 2/7/96 
  

			
		
	 By:
	 	 /s/ Mark Leslie

	 Name:
	 	 Mark Leslie

	 Title:
	 	 Trustee

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 

WALDEN RIVERWOOD VENTURES, LP 
  

			
	 By:
	 	 Walden Riverwood Ventures, LP

	 Its:
	 	 General Partner

		
	 By:
	 	 /s/ Lip-Bu
Tan

		 	 Lip-Bu Tan, Director

 WRV II, LLC 
  

			
	 By:
	 	 WRV II, LLC

	 Its:
	 	 General Partner

		
	 By:
	 	 /s/ Lip-Bu
Tan

		 	 Lip-Bu Tan, Director

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 WRV-BLI LLC 

 

			
	 By:
	 	 WIIG Communications Management LLC

	 Its:
	 	 Manager

		
	 By:
	 	 /s/ Lip-Bu
Tan

	 Name:
	 	 Lip-Bu Tan

	 Title:
	 	 Director

 WRV-BLI II LLC 

 

			
	 By:
	 	 WIIG Communications Management LLC

	 Its:
	 	 Manager

		
	 By:
	 	 /s/ Lip-Bu
Tan

	 Name:
	 	 Lip-Bu Tan

	 Title:
	 	 Director

 WRV-BLI III LLC 

 

			
	 By:
	 	 WIIG Communications Management LLC,

its Manager

		
	 By:
	 	 /s/ Lip-Bu
Tan

	 Name:
	 	 Lip-Bu Tan

	 Title:
	 	 Director

	
	 c/o Walden International

333 Bush St, Suite 2800 San

	 Francisco, CA 94104

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 

METNI HOLDINGS, L.P. 
  

			
		
	 By:
	 	 /s/ Alan Metni

	 Name:
	 	 Alan Metni

	 Title:
	 	 Pres., Metni Holdings G.P.-

General Partner

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 

BLACK DIAMOND VENTURES XXII, LLC 
  

			
	 By:
	 	 Black Diamond Ventures Manager

XXII, LLC, its Manager

		
	 By:
	 	 /s/ Christopher B. Lucas

	 Name:
	 	 Christopher B. Lucas

	 Title:
	 	 Managing Director

	
	 c/o Black Diamond Ventures, LLC

	 Ana Quintana 450 N. Brand Blvd., Suite 600

	 Glendale, CA 91203

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 COTA CAPITAL MASTER FUND, L.P. 
  

			
	 By:
	 	 Cota Capital GP, LLC

	 Its:
	 	 General Partner

		
	 By:
	 	 /s/ Babak Poushanchi

	 Name:
	 	
	 Title:
	 	 Manager

		
	 Address:
	 	 455 Market Street, Suite 1850

		 	 San Francisco, CA 94105

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 

VARIAN MEDICAL SYSTEMS, INC. 
  

			
		
	 By:
	 	 /s/ Rafael Torres

	 Name:
	 	 Rafael Torres

	 Title:
	 	 SVP of Strategy and

Business Development

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 

EDWARD AND KAREN GILHULY TRUST DTD 8/3/93 
  

			
		
	 By:
	 	 /s/ Ned Gilhuly

	 Name:
	 	 Ned Gilhuly

	 Title:
	 	 Trustee

		
	 Address:
	 	 245 Lytton Avenue, Suite 250

		 	 Palo Alto, CA 94301

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 COTA OPPORTUNITIES II, LLC 
  

			
	 By:
	 	 Cota Capital GP, LLC

	 Its:
	 	 Manager

		
	 By:
	 	 /s/ Babak Poushanchi

	 Name:
	 	 Babak Poushanchi

	 Title:
	 	 Manager

		
	 Address:
	 	 455 Market Street, Suite 1850

		 	 San Francisco, CA 94105

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 KTB CHINA SYNERGY FUND, 

acting through KTB NETWORK CO., LTD., 
 its general
partner 
  

			
		
	 By:
	 	 /s/ Jin Ho Shin

	 Name:
	 	 Jin Ho Shin

	 Title:
	 	 Chief Executive Officer

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 

ATINUM GROWTH FUND 2018 
 acting through Atinum Investment
Co, Ltd., 
 its General Partner 
  

			
	 By:
	 	 /s/ Ki Chun Shin

	Name:	 	 Ki Chun Shin

	Title:	 	 C.E.O.

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 

THE MARKS FAMILY TRUST 
  

			
	 By:
	 	 /s/ Michael E Marks

	 Name:
	 	 Michael E Marks

	 Title:
	 	 Trustee

	
	 Michael E Marks

c/o Allison Halen

	 Paxion Capital LP

2494 Sand Hill Road

	 Menlo Park, CA 94025

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 

BERKELEY MACK, LLC 

			
	 By: Mack & Co., LLC

	 Its: Managing Member

		
	 By:
	 	 /s/ Roszell Mack III

	 Name:
	 	 Roszell Mack III

	 Title:
	 	 President and Managing Member

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 

EMERGING TECHNOLOGIES FUND II LLC 

			
	
	 By: Open Field Capital II LLC, its Manager

	
	 By: Open Field Capital LLC, its Managing Member

		
	 By:
	 	 /s/ Marc Weiss

	 Name:
	 	 Marc Weiss

	 Title:
	 	 Manager

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 

SHANGBAY CAPITAL 

			
		
	 By:
	 	 
	 Name:
	 	
	 Title:
	 	
	
	 HONG KE, LP

	
	 By: ShangBay Capital, its General Partner

		
	 By:
	 	 /s/ Hong, KE

	 Name:
	 	 Hong, KE

	 Title:
	 	

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 

DAVID AND HALEY LAMEY 
  

			
		
	 By:
	 	 /s/ David Lamey

	 Name:
	 	 David Lamey

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 

OFPP LLC 
  

			
	 By: OFPP Management LLC, its Manager

		
	 By:
	 	 /s/ Marc Weiss

	 Name:
	 	 Marc Weiss

	 Title:
	 	 Manager

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 

JTC BLI, LLC 
  

			
		
	 By:
	 	 /s/ Jose Medeiros

	 Name:
	 	 Jose Medeiros

	 Title:
	 	 Managing Member

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of
the date first written above. 
 INVESTOR: 

SHANGBAY CAPITAL, LLC 
  

			
		
	 By:
	 	 /s/ William Dai

	 Name:
	 	 William Dai

	 Title:
	 	Founding Partner

 HONG KE, LP 
  

			
	 By:
	 	 ShangBay Capital, LLC, its General Partner

		
	 By:
	 	 
	 Name:
	 	
	 Title:
	 	

  
 [SIGNATURE
PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 EXHIBIT A 

Schedule of Investors 
  

															
	 Name, Address and
E-Mail
	  	Series A
Shares	  	Series A-1
Shares	  	Series A-2
Shares	  	Series B
Shares	  	Series C
Shares	  	Series D
Shares	  	Series E
Shares
								
	 The Khandros-Bloch Revocable Trust
 U/A/D
1/24/1997
 ######################
 ###############

#############
 Igor.Khandros@berkeleylights.com
	  	5,000,000	  	2,500,002	  	11,415,525	  	3,852,215	  		  	74,294	  	
								
	 The Khandros 1997 Trust I
 Attn: Robert S.
Bradley, Trustee
 c/o Howson & Simon LLP
 101 Ygnacio
Valley Road #310
 Walnut Creek, CA 94596
	  	500,000	  		  		  		  		  		  	
								
	 The Khandros 1997 Trust II
 Attn: Robert S.
Bradley, Trustee
 c/o Howson & Simon LLP
 101 Ygnacio
Valley Road #310
 Walnut Creek, CA 94596
	  	500,000	  		  		  		  		  		  	
								
	 Bill’s Trust U/A Leonard S. Davidow
 Attn:
William H. Davidow, Trustee
	  	1,200,000	  	500,000	  	2,634,351	  		  		  		  	
								
	 Davidow Descendants Trust
 #############

#############
 #############
	  		  		  		  	885,368	  		  		  	
								
	 The Davidow Family Trust
 ###########

###############
 Attn: ##############
	  		  		  		  	1,381,932	  		  		  	

															
	 Name, Address and
E-Mail
	  	Series A
Shares	  	Series A-1
Shares	  	Series A-2
Shares	  	Series B
Shares	  	Series C
Shares	  	Series D
Shares	  	Series E
Shares
								
	 Walden Riverwood Ventures, L.P.
 One California
Street
 Suite 2800
 San Francisco, CA 94111

###################
 F: ##########

P: ##########
	  		  		  		  	4,659,832	  	1,706,484	  		  	
								
	 WRV-BLI LLC

c/o Walden International
 One California St.

Suite 2800
 San Francisco, CA 94111 

#################
	  		  		  		  	12,152,843	  		  		  	
								
	 WRV-BLI II LLC

c/o Walden International One
 California St.

Suite 2800
 San Francisco, CA 94111

###################
	  		  		  		  		  	3,917,574	  		  	
								
	 WRV II, L.P.
 c/o Walden International

One California St.
 Suite 2800

San Francisco, CA 94111
 ###################
	  		  		  		  		  		  	1,485,884	  	383,310
								
	 Mathieu Family Trust U/A DTD
 9/17/2004

###################
 ####################

Attn: #############
	  		  		  		  	609,528	  		  		  	
								
	 FKS Investments VIII LLC
 7 Times Square

28th Floor
 New York, NY 10036

#################
	  		  		  		  	1,218,099	  		  	29,717	  	27,023

  
 2 

															
	 Name, Address and
E-Mail
	  	Series A
Shares	  	Series A-1
Shares	  	Series A-2
Shares	  	Series B
Shares	  	Series C
Shares	  	Series D
Shares	  	Series E
Shares
								
	 Prestridge 1989 Family Trust

###################
 ############

Attn: ################
	  		  		  		  	1,002,662	  		  		  	60,017
								
	 Lone Tree WY LLC
 ###################

############
 Attn: ################
	  		  		  		  	214,958	  		  	29,717	  	170,066
								
	 Yoshikazu & Setsuko Hatsukano

################
 #############

############
	  		  		  		  	607,693	  		  		  	
								
	 Dan Maydan TTEE Marital Share 1

#################
 ####################

Attn: #########
	  		  		  		  	479,463	  		  		  	
								
	 The Robert and Patricia Bradley
 Family Trust
U/A/D 9/25/2008
 ###############
 #################

Attn: #############
	  		  		  		  	119,910	  		  		  	
								
	 Sequoia Capital U.S. Growth Fund
 VI, L.P.

c/o Sequoia Capital
 2800 Sand Hill Road #101

Menlo Park, CA 94025
 ###################
	  		  		  		  		  	9,100,478	  	1,028,886	  	663,549
								
	 Sequoia Capital U.S. Growth VI
 Principals Fund,
L.P.
 c/o Sequoia Capital
 2800 Sand Hill Road #101

Menlo Park, CA 94025
 ##################
	  		  		  		  		  	455,836	  	11,233	  	7,244

  
 3 

															
	 Name, Address and
E-Mail
	  	Series A
Shares	  	Series A-1
Shares	  	Series A-2
Shares	  	Series B
Shares	  	Series C
Shares	  	Series D
Shares	  	Series E
Shares
								
	 Sequoia Capital U.S. Venture Fund
 XV, L.P.

c/o Sequoia Capital
 2800 Sand Hill Road #101

Menlo Park, CA 94025
 ###################
	  		  		  		  		  	3,410,375	  	371,189	  	237,374
								
	 Sequoia Capital U.S. Venture Partners
 Fund XV
(Q), L.P.
 c/o Sequoia Capital
 2800 Sand Hill Road #101

Menlo Park, CA 94025
 ###################
	  		  		  		  		  	120,000	  	13,061	  	10,004
								
	 Sequoia Capital U.S. Venture Partners
 Fund XV,
L.P.
 c/o Sequoia Capital
 2800 Sand Hill Road #101

Menlo Park, CA 94025
 ###################
	  		  		  		  		  	41,365	  	4,502	  	3,593
								
	 Sequoia Capital U.S. Venture XV
 Principals
Fund, L.P.
 c/o Sequoia Capital
 2800 Sand Hill Road #101

Menlo Park, CA 94025
 ###############
	  		  		  		  		  	523,823	  	57,013	  	36,510
								
	 Paxion Capital, LP
 2494 Sand Hill Road

Suite 100
 Menlo Park, CA 94025

###############
	  		  		  		  		  		  	1,485,884	  	574,965
								
	 Metni Holdings, LP
 8905 Mountbatten Circle

Austin, TX 78730
 ################
	  		  		  		  		  		  	594,353	  	95,827

  
 4 

															
	 Name, Address and
E-Mail
	  	Series A
Shares	  	Series A-1
Shares	  	Series A-2
Shares	  	Series B
Shares	  	Series C
Shares	  	Series D
Shares	  	Series E
Shares
								
	 Lucas Venture Group IV, LP
 545 Middlefield
Road
 Suite 220
 Menlo Park, CA 94025

#############
	  		  		  		  		  		  	104,011	  	
								
	 Lucas Venture Group V, LP
 545 Middlefield
Road
 Suite 220
 Menlo Park, CA 94025

#############
	  		  		  		  		  		  	74,294	  	
								
	 Lucas Venture Group XXII, LLC
 545 Middlefield
Road
 Suite 220
 Menlo Park, CA 94025

#################
	  		  		  		  		  		  	199,108	  	25,873
								
	 Black Diamond Ventures XXII, LLC
 400 N. Brand
Blvd.
 Suite 950
 Glendale, CA 91203

#####################
	  		  		  		  		  		  	1,040,118	  	705,100
								
	 SST Holdings, Incorporated
 Craig Chambers

P.O. Box 71
 Road Town, Tortola

VG 1110
 British Virgin Islands

Attn. Lubna Olayan
 #####################
	  		  		  		  		  		  	297,176	  	191,655

  
 5 

															
	 Name, Address and
E-Mail
	  	Series A
Shares	  	Series A-1
Shares	  	Series A-2
Shares	  	Series B
Shares	  	Series C
Shares	  	Series D
Shares	  	Series E
Shares
								
	 Nikon Corporation
 Healthcare Business Unit,
Nikon Corporation
 2-15-1, Konan,
Minato-ku, Tokyo
 108-6290 Japan

Phone: ###########
 Attn: ##############

Email:
 ############################

Attn: ##############
 Email:

#########################
	  		  		  		  		  		  	2,971,768	  	5,749,659
								
	 Leslie Family Trust U/A 2/7/96

#################
 #####################

Attn: ##############
	  		  		  		  		  		  		  	191,655
								
	 Cota Capital Master Fund, L.P.
 455 Market
Street
 Suite 1950
 San Francisco, CA 94105
	  		  		  		  		  		  		  	1,964,466
								
	 WRV-BLI III LLC

c/o Walden International
 One California St.

Suite 2800
 San Francisco, CA 94111

##################
	  		  		  		  		  		  	1,930,828	  	
								
	 WRV-BLI IV LLC

c/o Walden International
 One California St.

Suite 2800
 San Francisco, CA 94111

##################
	  		  		  		  		  		  		  	1,087,960

  
 6 

															
	 Name, Address and
E-Mail
	  	Series A
Shares	  	Series A-1
Shares	  	Series A-2
Shares	  	Series B
Shares	  	Series C
Shares	  	Series D
Shares	  	Series E
Shares
								
	 Cota Opportunities II, LLC
 455 Market
Street
 Suite 1850
 San Francisco, CA 94105
	  		  		  		  		  		  		  	335,396
								
	 Edward and Karen Gilhuly Trust DTD
 8/3/93

245 Lytton Avenue
 Suite 250

Palo Alto, CA 94301
	  		  		  		  		  		  		  	287,482
								
	 Varian Medical Systems, Inc.
 3100 Hansen
Way
 Palo Alto, CA 94304
 Attn: Jon Kuo, General
Counsel
	  		  		  		  		  		  		  	574,965
								
	 KTB China Synergy Fund
 10FL, 670 Daewangpanyo-RO
 Sungam 13494

South Korea
	  		  		  		  		  		  		  	1,000,000
								
	 Atinum Growth Fund 2018
 2F, Je-il Bldg. 9,
 Teheran-ro 103-gil, Gagnam-gu,
 Seoul, 06173

Korea
	  		  		  		  		  		  		  	1,000,000
								
	 OFPP LLC
 1140 Avenue of the Americas

9th Floor
 New York New York 10036
	  		  		  		  		  		  		  	95,827
								
	 ShangBay Capital, LLC
 530 Lytton Ave

2nd Floor
 Palo Alto, CA 94301
	  		  		  		  		  		  		  	479,138

  
 7 

															
	 Name, Address and
E-Mail
	  	Series A
Shares	  	Series A-1
Shares	  	Series A-2
Shares	  	Series B
Shares	  	Series C
Shares	  	Series D
Shares	  	Series E
Shares
								
	 Hong Ke, LP
 ##############

###############
	  		  		  		  		  		  		  	479,138
								
	 Silver Harvest Ventures Limited
 P.O. Box 957
Offshore Incorporations
 Centre Road Town,
 Tortola, British
Virgin Islands
	  		  		  		  		  		  		  	958,276
								
	 Emerging Technologies Fund II LLC
 1140 Avenue
of the Americas
 9th Floor
 New York New York 10036
	  		  		  		  		  		  		  	143,741
								
	 JTC BLI, LLC
 2494 Sand Hill Road

Menlo Park, CA 94025
	  		  		  		  		  		  		  	253,943
								
	 David and Haley Lamey
 ##############

############
	  		  		  		  		  		  		  	20,000
								
	 Berkeley Mack LLC
 590 Madison Ave

21st Floor
 New York, NY 10022
	  		  		  		  		  		  		  	355,041
								
	 The Marks Family Trust
 Michael E Marks

c/o Allison Halen
 Paxion Capital LP

2494 Sand Hill Road
 Menlo Park, CA 94025
	  		  		  		  		  		  		  	38,460

  
 8EX-4.4

 Exhibit 4.4 
  

 
 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933
AS AMENDED (the “1933 ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL REASONABLY
SATISFACTORY TO YOU THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE 1933 ACT, OR ANY APPLICABLE STATE SECURITIES LAWS. 
 PLAIN ENGLISH
WARRANT AGREEMENT 
 This is a PLAIN ENGLISH WARRANT AGREEMENT dated August 24, 2016 by and between BERKELEY LIGHTS, INC., a Delaware
corporation, and TRIPLEPOINT CAPITAL LLC, a Delaware limited liability company. 
 The words “We”, “Us”, or “Our” refer to the
warrant holder, which is TRIPLEPOINT CAPITAL LLC. The words “You” or “Your” refers to the issuer, which is BERKELEY LIGHTS, INC., and not to any individual. The words “the Parties” refers to both TRIPLEPOINT CAPITAL LLC
and BERKELEY LIGHTS, INC. This Plain English Warrant Agreement may be referred to as the “Warrant Agreement”. 
 The Parties have entered into a
Plain English Growth Capital Loan and Security Agreement dated as of August 24, 2016, the “Loan Agreement”. 
 In consideration of such Loan
Agreement, the Parties agree to the following mutual agreements and conditions set forth below: 
  

					
	WARRANT INFORMATION
			
	 Effective Date
	  	 Warrant Number
	  	 Loan Facility
Number

	August 24, 2016	  	0970-W-01	  	Part 1: 0970-GC-01
		  		  	Part 2: 0970-GC-02

 

							
	 Warrant Coverage
	  	 Number of Shares
	  	 Price Per Share
	  	 Type of Stock

	 Part 1: $800,000 (4.0% of $20,000,000) on the Effective Date

 
 Part 2: $200,000
(4.0% of $5,000,000) on the Availability of the Part 2 Commitment Amount under the Loan Agreement
	  	 Part 1: 273,038 on the Effective Date, subject to adjustment as set forth in this Warrant Agreement

 
 Part 2: 68,259 on the Availability of the Part 2 Commitment
Amount under the Loan Agreement, subject to adjustment as set forth in this Warrant Agreement
	  	$2.93, subject to adjustment as set forth in this Warrant Agreement	  	Series C Preferred Stock, subject to adjustment as set forth in this Warrant Agreement

  

					
	OUR CONTACT INFORMATION
			
	 Name
	  	 Address For Notices
	  	 Contact Person

	TriplePoint Capital LLC	  	2755 Sand Hill Road, Ste. 150
Menlo Park, CA 94025
Tel: (650) 854-2090
Fax: (650) 854-1850	  	Sajal Srivastava, President
Tel: (650) 233-2102
Fax: (650) 854-1850 email: legal@triplepointcapital.com
	
	YOUR CONTACT INFORMATION
			
	 Customer Name
	  	 Address For Notices
	  	 Contact Person

	Berkeley Lights, Inc.	  	5858 Horton Street, Suite 320
Emeryville, CA 94608	  	Shaun Holt, CFO
Tel: 858-525-1421
Fax: N/A
email:shaun.holt@berkeleylights.com

  

			
	Warrant (Loan) 0970-W-01	  	1

	1.	 WHAT YOU AGREE TO GRANT US 

Part 1: You grant to Us and We are entitled, upon the terms and subject to the conditions set forth in this Warrant Agreement, to purchase from You, at
a price per share equal to the Exercise Price, that number of fully paid and non-assessable shares of Your Warrant Stock equal to Eight Hundred Thousand Dollars ($800,000), divided by the Exercise Price. 

Part 2: Upon the availability of Part 2 under the Loan Agreement, You grant to Us and We are entitled, upon the terms and subject to the conditions set
forth in this Warrant Agreement, to purchase from You, at a price per share equal to the Exercise Price, an additional number of fully paid and non-assessable shares of Your Warrant Stock equal to Two Hundred
Thousand Dollars ($200,000), divided by the Exercise Price. 
 The number of shares of Warrant Stock and the Exercise Price of such Warrant Stock are
subject to adjustment as provided in Section 4 hereof. 
 For purposes of this Warrant Agreement, the following capitalized terms have the meanings
given below: 
 “Exercise Price” means the lower of (a) $2.93 and (b) the lowest per share price for which Your preferred stock is sold in
the Next Round. 
 “Next Round” means the next bona fide round of equity financing in which You issue and sell shares of your preferred stock for
aggregate gross cash proceeds of at least $1,000,000 (excluding any amounts received upon conversion or cancellation of indebtedness) subsequent to the Effective Date. 

“Warrant Stock” means (a) the class and series of Your preferred stock issued in the Next Round, if the lowest per share price for which such
preferred stock is sold in the Next Round is less than $2.93, or (b) in all other cases, Your Series C Preferred Stock. For avoidance of doubt, if this Warrant Agreement is exercised prior to the Next Round then this Warrant Agreement shall be
exercisable for Your Series C Preferred Stock. 
 The Parties agree that this Warrant Agreement to purchase the Warrant Stock has a fair market value equal
to $100 and that $100 of the issue price of the investment will be allocable to the Warrant Agreement and the balance shall be allocable to the Loan Agreement for income tax purposes and the original issue discount on the Loan Agreement shall be
considered to be zero. 
  

	2.	 WHEN ARE WE ENTITLED TO PURCHASE YOUR WARRANT STOCK. 

The term of this Warrant Agreement and Our right to purchase Warrant Stock will begin the Effective Date, and shall be available for the greater of (i) 7 years
from the Effective Date or (ii) 5 years from the effective date of Your initial public offering. 
 Notwithstanding the foregoing, Our right to purchase the
Warrant Stock shall be automatically and fully exercised via the net issuance method described below (without surrender of the Warrant Agreement) upon the occurrence of a Merger Event, as defined below, with a Person that is not one of Your
affiliates, in which Your common stock is exchanged for cash and/or stock that is traded on a recognized public exchange or on the NASDAQ National Market, provided that, upon consummation of the Merger Event, the consideration payable to Us pursuant
to such exercise and on account of the Warrant Stock consists of (i) cash or (ii) stock 

  

			
	Warrant (Loan) 0970-W-01	  	2

 
that is traded on a recognized public exchange or on the NASDAQ National Market and the total per share consideration is equal to or greater than two (2) times the aggregate Exercise Price
(as adjusted). No less than ten (10) business days prior to any Merger Event, You shall provide Us with written notice of the proposed Merger Event together with a copy of the executed merger agreement, or other definitive documentation (and
all schedules and exhibits thereto) and information concerning Your expected capitalization immediately prior to the Merger Event. Upon consummation of the Merger Event, You shall promptly provide Us with (a) a copy of any modifications or
amendments to the executed merger agreement, (b) any other documents in connection therewith, (c) updated information, if any, concerning Your capitalization immediately prior to the Merger Event, and, (d) upon request, by Us any
other information reasonably necessary to an informed evaluation of Our rights under this Agreement. 
  

	3.	 HOW WE MAY PURCHASE YOUR WARRANT STOCK. 

We may exercise Our purchase rights, in whole or in part, at any time, or from time to time, prior to the expiration of the term of this Warrant Agreement, by
giving You a completed and executed Notice of Exercise in the form attached as Exhibit I. Promptly upon receipt of the Notice of Exercise and in any event no later than twenty-one (21) days
after you have received Our Notice of Exercise and payment of the aggregate Exercise Price for the shares purchased, You will issue to Us a certificate for the number of shares of Warrant Stock that We have purchased and You will execute the
Acknowledgment of Exercise in the form attached hereto as Exhibit II indicating the number of shares which will be available to Us for future purchases, if any. 

We may pay for the Warrant Stock by either (i) cash or check, or (ii) by the net issuance method as determined below. If We elect the Net
Issuance method, You will issue Warrant Stock using the following formula: 
  
 

 
  

			
	 Where:
	  	X = the number of shares of Warrant Stock to be issued to Us.
		  	Y = the number of shares of Warrant Stock We request to be exercised under this Warrant Agreement.
		  	A = the fair market value of one share of Warrant Stock.
		  	B = the Exercise Price.

 For purposes of the above calculation, current fair market value of Warrant Stock shall mean with respect to each share of
Warrant Stock: 
 If the exercise is in connection with but not after the initial public offering of Your Common Stock, and if Your registration
statement relating to such public offering has been declared effective by the SEC, then the fair market value per share shall be the product of (x) the initial “Price to Public” specified in the final prospectus of the offering and
(y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise; 

  

			
	Warrant (Loan) 0970-W-01	  	3

 If this Warrant Agreement is exercised after, and not in connection with Your initial public offering,
and: 
  

	Þ	 if traded on a securities exchange, the fair market value shall be the product of (x) the average
of the closing prices over a five (5) day period ending three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Warrant
Stock is convertible at the time of such exercise; or 

  

	Þ	 if actively traded
over-the-counter, the fair market value shall be the product of (x) the average of the closing bid and asked prices quoted on the NASDAQ system (or similar system)
over the five (5) day period ending three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible
at the time of such exercise. 

 If this Warrant Agreement is exercised prior to or after Your initial public offering, and: 

 

	Þ	 Your Common Stock is not listed on any securities exchange or quoted in the NASDAQ System or the over-the-counter market, the current fair market value of Warrant Stock shall be the product of (x) the fair market value of a share of Your Common Stock, as determined
in good faith by Your Board of Directors and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise, unless You shall become subject to a merger, acquisition or other
consolidation pursuant to which You are not the surviving party, in which case the fair market value of Warrant Stock shall be deemed to be the value received by the holders of Your Warrant Stock on a common equivalent basis pursuant to such merger
or acquisition or other consolidation. 

 During the term of this Warrant Agreement, You will at all times from and after the Effective
Date have authorized and reserved a sufficient number of shares of (a) Warrant Stock to provide for the exercise of our rights to purchase Warrant Stock, and (b) Common Stock to provide for the conversion of the Warrant Stock. 

If We elect to exercise part of the Warrant Agreement, You will promptly issue to Us an amended Warrant Agreement stating the remaining number of shares that
are available. All other terms and conditions of that amended Warrant Agreement shall be identical to those contained in this Warrant Agreement. 
 If at
the end of the term of this Warrant Agreement, the fair market value of one share of Warrant Stock (or other security issuable upon the exercise hereof) as determined in accordance herewith is greater than the Exercise Price in effect on such date,
then this Warrant Agreement shall automatically be deemed on and as of such date to be converted pursuant hereto as to all shares of Warrant Stock (or such other securities) for which it shall not previously have been exercised or converted, and You
shall promptly deliver a certificate representing the shares of Warrant Stock (or such other securities) issued upon such conversion to Us. 

  

			
	Warrant (Loan) 0970-W-01	  	4

	4.	 WHEN WILL THE NUMBER OF SHARES AND EXERCISE PRICE CHANGE. 

 

	Þ	 If You are Acquired. If at any time: (i) there is a reorganization of Your stock (other than a
reclassification, exchange or subdivision of Your stock otherwise provided for in this Warrant Agreement); (ii) You merge or consolidate with or into another entity, whether or not You are the surviving entity; (iii) You sell or convey, or
grant an exclusive license with respect to, all or substantially all of Your assets to any other person; or (iv) there occurs any transaction or series of related transactions that result in the transfer of fifty percent (50%) or more of the
outstanding voting power of the capital stock of You (each of the foregoing events are referred to as a “Merger Event”), then, as a part of such Merger Event, lawful provision shall be made so that We shall thereafter be entitled to
receive, upon exercise of Our rights under this Warrant Agreement, the number of shares of preferred stock or other securities of the successor or surviving person resulting from such Merger Event, that would have been issuable if We had exercised
Our rights under this Warrant Agreement immediately prior to the Merger Event. In any such case, appropriate adjustment (as determined in good faith by Your Board of Directors) shall be made in the application of the provisions of this Warrant
Agreement with respect to Our rights and interest after the Merger Event so that the provisions of this Warrant Agreement (including adjustments of the Exercise Price and number of shares of Warrant Stock purchasable) shall be applicable to the
greatest extent possible. 

  

	Þ	 If You Reclassify Your Stock. If at any time You reclassify or subdivide Your securities or otherwise
change any of the securities as to which purchase rights under this Warrant Agreement exist into the same or a different number of securities of any other class or classes, this Warrant Agreement will thereafter represent the right to acquire such
number and kind of securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this Warrant Agreement immediately prior to such combination, reclassification,
exchange, subdivision or other change. 

  

	Þ	 If You Subdivide or Combine Your Shares. If at any time You combine or subdivide the Warrant Stock, the
Exercise Price will be proportionately decreased in the case of a subdivision, or proportionately increased in the case of a combination. 

  

	Þ	 If You Pay Stock Dividends. If at any time You pay a dividend payable in, or make any other distribution
(except any distribution specifically provided for in the above paragraphs) of the Warrant Stock, then the Exercise Price shall be adjusted, from and after the record date of such dividend or distribution, to that price determined by multiplying the
Exercise Price in effect immediately prior to such record date by a fraction (i) the numerator of which shall be the total number of all shares of the Warrant Stock outstanding immediately prior to such dividend or distribution, and
(ii) the denominator of which shall be the total number of all shares of the Warrant Stock outstanding immediately after such dividend or distribution. We will thereafter be entitled to purchase, at the Exercise Price resulting from such
adjustment, the number of shares of Warrant Stock (calculated to the nearest whole share) obtained by multiplying the Exercise Price in effect immediately prior to such adjustment by the number of shares of Warrant Stock issuable upon the exercise
hereof immediately prior to such adjustment and dividing the product thereof by the Exercise Price resulting from such adjustment. 

  

			
	Warrant (Loan) 0970-W-01	  	5

	Þ	 “Pay to Play” Rights. In the event that any “pay to play” terms or conditions (i.e.
terms or conditions that require a holder of shares of Your preferred stock (the “Preferred Stock”) to purchase securities in a future round of equity financing or else lose the benefit of anti-dilution protections applicable to shares of
Preferred Stock or have such shares of Preferred Stock automatically convert into Common Stock or another class or series of capital stock) in Your Certificate of Incorporation are triggered in connection with any sale or issuance of securities (a
“Trigger Event”), then, in each such event the purchase rights under this Warrant Agreement shall automatically adjust to provide Us, upon the later exercise hereof, with the same securities and/or rights that We would have received had We
(x) exercised this Warrant Agreement prior to such Trigger Event, and (y) participated in the applicable equity financing in an amount sufficient to be deemed to have fully participated for purposes of such “pay to play”
provision. 

  

	Þ	 If You Change the Antidilution Rights of the Warrant Stock or Issue New Preferred or Convertible Stock.
All antidilution rights applicable to the Warrant Stock purchasable under this Warrant Agreement are as set forth in Your Certificate of Incorporation, as amended through the Effective Date. You will promptly provide Us with any restatement,
amendment, modification of or waiver of any right under Your Certificate of Incorporation. You will provide Us with copies of any notices that You send to Your stockholders with respect to any issuance of Your stock or other equity security to occur
after the Effective Date (other than issuances of stock or equity securities pursuant to customary employee stock plans). 

  

	5.	 WE CAN TRANSFER THIS PLAIN ENGLISH WARRANT AGREEMENT. 

Subject to the terms and conditions contained in Section 7, We (or any successor transferee) may transfer in whole or in part this Warrant Agreement and
all its rights, provided that as a condition of any such transfer, the transferee agrees to be bound by the terms of this Warrant Agreement. You will record the transfer on Your books when You receive Our Notice of Transfer in the form attached
hereto as Exhibit III, and Our payment of all transfer taxes and other governmental charges involved in such transfer. 
  

	6.	 REPRESENTATIONS, WARRANTIES, AND COVENANTS FROM YOU. 

 

	Þ	 Reservation of Warrant Stock. The Warrant Stock issuable upon exercise of Our rights under this Warrant
Agreement will be duly and validly reserved and when issued in accordance with the provisions of this Warrant Agreement will be validly issued, fully paid and non-assessable, and will be free of any taxes,
liens, charges or encumbrances of any nature whatsoever (other than liens or encumbrances created by or imposed by Us); provided, however, that the Warrant Stock issuable pursuant to this Warrant Agreement may be subject to restrictions on transfer
under state and/or Federal securities laws. Upon Our exercise, You will issue to Us certificates for shares of Warrant Stock without charging Us any tax, or other cost incurred by You in connection with such exercise and the related issuance of
shares of Warrant Stock. You will not be required to pay any tax, which may be payable in respect of any transfer involved and the issuance and delivery of any certificate in a name other than TriplePoint Capital LLC. 

  

			
	Warrant (Loan) 0970-W-01	  	6

	Þ	 Due Authority. Your execution and delivery of this Warrant Agreement and the performance of Your
obligations hereunder, including the issuance to Us of the right to acquire the shares of Warrant Stock, have been duly authorized by all necessary corporate action on Your part and this Warrant Agreement is not inconsistent with Your Certificate of
Incorporation or Bylaws, do not contravene any law or governmental rule, regulation or order applicable to it, do not and will not contravene any material provision of, or constitute a material default under, any indenture, mortgage, material
contract or other instrument to which You are a party or by which You are bound, and this Warrant Agreement constitutes a legal, valid and binding agreement, enforceable in accordance with its respective terms, subject to laws of general application
relating to bankruptcy, insolvency and the relief of debtors and the rules of law or principles at equity governing specific performance, injunctive relief and other equitable remedies. 

 

	Þ	 Consents and Approvals. No consent or approval of, giving of notice to, registration with, or taking of
any other action in respect of any state, Federal or other governmental authority or agency is required with respect to execution, delivery and Your performance of Your obligations under this Warrant Agreement, except for the filing of any required
notices pursuant to Federal and state securities laws, which filings will be effective by the times required thereby. 

  

	Þ	 Issued Securities. All of Your issued and outstanding shares of Common Stock, Warrant Stock or any other
securities have been duly authorized and validly issued and are fully paid and nonassessable. All outstanding shares of Common Stock and Warrant Stock were issued in full compliance with all Federal and state securities laws. In addition as of the
Effective Date: 

 Your authorized capital consists of (A) 85,000,000 shares of Common Stock, of which 4,688,129 shares of Common Stock
are issued and outstanding, and (B) 71,554,561 shares of preferred stock, of which 70,710,496 shares are issued and outstanding. 
 You have reserved
10,000,000 shares of Common Stock for issuance under Your Stock Incentive Plan, under which 7,846,995 options have been granted and remain outstanding. Except as otherwise provided in this Warrant Agreement and as noted above, there are no other
options, warrants, conversion privileges or other rights presently outstanding to purchase or otherwise acquire any authorized but unissued shares of Your capital stock or other of Your securities. 

Except as set forth in the Rights Agreement, a true, correct and complete copy of which has been delivered to Us prior to the issuance of this Warrant, Your
stockholders do not have preemptive rights to purchase new issuances of Your capital stock. 
  

	Þ	 Other Commitments to Register Securities. Except as set forth in this Warrant Agreement and the Rights
Agreement, You are not, pursuant to the terms of any other agreement currently in existence, under any obligation to register under the 1933 Act any of Your presently outstanding securities or any of Your securities which may hereafter be issued.

  

	Þ	 Exempt Transaction. Subject to the accuracy of Our representations in Section 7 hereof, the
issuance of the Warrant Stock upon exercise of this Warrant Agreement will constitute a transaction exempt from (i) the registration requirements of Section 5 of the 1933 Act, in reliance upon Section 4(2) thereof, and (ii) the
qualification requirements of the applicable state securities laws. 

  

			
	Warrant (Loan) 0970-W-01	  	7

	Þ	 Compliance with Rule 144. Subject to the other restrictions set forth in this Warrant Agreement, We may
sell the Warrant Stock issuable hereunder in compliance with Rule 144 promulgated by the Securities and Exchange Commission. Within ten (10) days of Our request, You agree to furnish Us, a written statement confirming Your compliance with the
filing requirements of the Securities and Exchange Commission as set forth in such Rule 144, as may be amended. 

  

	Þ	 No Impairment. You agree not to, by amendment of Your Certificate of Incorporation, by-laws or other organizational or charter documents or through a reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to
avoid the observance or performance of any of the terms to be observed or performed under this Warrant by You, but shall at all times in good faith assist in carrying out of all the provisions of this Warrant and in taking all such action as may be
necessary or appropriate to protect Our rights under this Warrant against impairment. However, You shall not be deemed to have impaired Our rights if You amend Your Certificate of Incorporation, or the holders of Your preferred stock waive their
rights thereunder, in a manner that does not (individually or when considered in the context of any other actions being taken in connection with such amendments or waivers) affect Us in a manner different from the effect that such amendments or
waivers have on the rights of other holders of the same series and class as the Warrant Stock; provided, however, that, notwithstanding the foregoing, You shall not impose any restrictions on the transferability or alienability of the
Warrant Stock other than in effect as of the Effective Date without the express written consent of Us. 

  

	7.	 OUR REPRESENTATIONS AND COVENANTS TO YOU. 

 

	Þ	 Investment Purpose. The right to acquire Warrant Stock or the Warrant Stock issuable upon exercise of
Our rights contained herein and the Common Stock issuable upon conversion will be acquired for investment purposes and not with a view to the sale or distribution of any part thereof, and We have no present intention of selling or engaging in any
public distribution of the same in violation of the 1933 Act. 

  

	Þ	 Private Issue. We understand (i) that this Warrant Agreement, the Warrant Stock issuable upon
exercise of this Warrant Agreement and the Common Stock issuable upon conversion of the Warrant Stock are not registered under the 1933 Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this
Warrant Agreement will be exempt from the registration and qualifications requirements thereof, and (ii) that Your reliance on such exemption is predicated on the representations set forth in this Section 7. 

 

	Þ	 Disposition of Our Rights. In no event will We make a disposition of any of Our rights to acquire
Warrant Stock or Warrant Stock issuable upon exercise of such rights or the Common Stock issuable upon conversion of the Warrant Stock unless and until (i) We shall have notified You in writing of the proposed disposition, and (ii) the
transferee agrees to be bound in writing to the applicable terms and conditions of this Warrant Agreement, and (iii) if You request, We shall have furnished You with an opinion of counsel satisfactory to You and Your counsel to the effect that
(A) appropriate action 

  

			
	Warrant (Loan) 0970-W-01	  	8

	 	
necessary for compliance with the 1933 Act has been taken, or (B) an exemption from the registration requirements of the 1933 Act is available. Notwithstanding the foregoing, the
restrictions imposed upon the transferability of any of Our rights to acquire Warrant Stock or Warrant Stock issuable on the exercise of such rights or the Common Stock issuable upon conversion of the Warrant Stock do not apply to transfers from the
beneficial owner of any of the aforementioned securities to its nominee or from such nominee to its beneficial owner, and shall terminate as to any particular share of Warrant Stock when (1) such security shall have been effectively registered
under the 1933 Act and sold by the holder thereof in accordance with such registration or (2) such security shall have been sold without registration in compliance with Rule 144 under the 1933 Act, or (3) a letter shall have been issued to
You at Our request by the staff of the Securities and Exchange Commission or a ruling shall have been issued to You at Our request by such Commission stating that no action shall be recommended by such staff or taken by such Commission, as the case
may be, if such security is transferred without registration under the 1933 Act in accordance with the conditions set forth in such letter or ruling and such letter or ruling specifies that no subsequent restrictions on transfer are required.
Whenever the restrictions imposed hereunder shall terminate, as hereinabove provided, the holder of a share of Warrant Stock then outstanding as to which such restrictions have terminated shall be entitled to receive from You, without expense to
such holder, one or more new certificates for the Warrant or for such shares of Warrant Stock not bearing any restrictive legend referring to 1933 Act registration or exemption. 

 

	Þ	 Financial Risk. We have such knowledge and experience in financial and business matters and knowledge of
Your business affairs and financial condition as to be capable of evaluating the merits and risks of Our investment, and have the ability to bear the economic risks of Our investment. 

 

	Þ	 Risk of No Registration. We understand that if You do not register with the Securities and Exchange
Commission pursuant to Section 12 of the Securities Exchange Act of 1934 (the “1934 Act”), or file reports pursuant to Section 15(d), of the 1934 Act, or if a registration statement covering the securities under the 1933 Act is
not in effect when We desire to sell (i) the rights to purchase Warrant Stock pursuant to this Warrant Agreement, or (ii) the Warrant Stock issuable upon exercise of the right to purchase, or (iii) the Common Stock issuable upon
conversion of the Warrant Stock, We may be required to hold such securities for an indefinite period. We also understand that any sale of Our right to purchase Warrant Stock or Warrant Stock or Common Stock issuable upon conversion of the Warrant
Stock, which might be made by it in reliance upon Rule 144 under the 1933 Act may be made only in accordance with the terms and conditions of that Rule. 

  

	Þ	 Accredited Investor. We are an “accredited investor” within the meaning of the Securities and
Exchange Rule 501 of Regulation D of the 1933 Act, as presently in effect. 

  

	Þ	 Market Stand-off. We agree to be bound by the market stand-off provisions set forth in Section 3.11 of that certain Third Amended and Restated Investors’ Rights Agreement by and among You and the investors listed on Exhibit A thereto dated
April 1, 2015 (the “Rights Agreement”). We also agree to sign the form of lock-up letter requested by Your underwriters in Your initial public offering, provided all other

  

			
	Warrant (Loan) 0970-W-01	  	9

	 	
stockholders bound by the market stand-off language in the Rights Agreement are similarly bound. Notwithstanding the foregoing, in no event shall such
market stand-off provisions or lock-up letter restrict Our ability to exercise Our purchase rights under this Warrant Agreement, including the transfer of Common Stock
to You solely to satisfy the exercise price pursuant to the Net Issuance Method. 

  

	8.	 NOTICES YOU AGREE TO PROVIDE US. 

You agree to give Us at least ten (10) days prior written notice of the following events: 

 

	Þ	 If You pay a Dividend or distribution declaration upon Your stock. 

 

	Þ	 If You offer for subscription pro-rata to the existing
stockholders additional stock or other equity rights. 

  

	Þ	 If You consummate or sign definitive documents providing for a Merger Event. 

 

	Þ	 If You have an initial public offering. 

 

	Þ	 If You dissolve or liquidate. 

All notices in this Section must set forth details of the event, how the event adjusts either Our number of shares or Our Exercise Price and the method used
for such adjustment. 
 Timely Notice. Your failure to timely provide such notice required above shall entitle Us to retain the benefit of the
applicable notice period notwithstanding anything to the contrary contained in any insufficient notice received by Us. 
  

	9.	 DOCUMENTS YOU WILL PROVIDE US. 

Upon signing this Warrant Agreement You will provide Us with: 
  

	Þ	 Executed originals of this Warrant Agreement, and all other documents and instruments that We may
reasonably require 

  

	Þ	 Secretary’s certificate of incumbency and authority 

 

	Þ	 Certified copy of resolutions of Your board of directors approving this Warrant Agreement

  

	Þ	 Certified copy of Your Certificate of Incorporation and by-laws
as amended through the Effective Date 

  

	Þ	 Current Rights Agreement 

So long as this Warrant Agreement is in effect, You shall provide Us with the following: 

 

	Þ	 Within ten (10) Business Days after the closing of any equity financing, or extension of an
existing round of equity financing, occurring after the Effective Date, in which You issue preferred stock or other securities You will provide Us with copies of the fully executed equity financing documents, including without limitation the related

  

			
	Warrant (Loan) 0970-W-01	  	10

	 	
stock purchase agreement, investors rights agreement, voting agreement, amended or restated Certificates of Incorporation, current capitalization table and other related documents.
Notwithstanding any term or condition contained in this Warrant Agreement to the contrary, Your failure to comply with this paragraph shall not constitute a default unless You have not provided the information requested within ten (10) days of
Our request. 

  

	Þ	 Within thirty (30) days after completion You shall provide Us with any 409A Valuation Reports or
other similar reports prepared for You. Notwithstanding any term or condition contained in this Warrant Agreement to the contrary, Your failure to comply with this paragraph shall not constitute a default unless You have not provided the information
requested within ten (10) days of Our request. 

  

	Þ	 After all obligations under the Loan Agreement have been finally paid in full, within thirty
(30) days after the end of each quarter, You will provide Us with (1) an unaudited income statement, statement of cash flows, and an unaudited balance sheet prepared in accordance with GAAP accompanied by a report detailing any material
contingencies, and (2) within one hundred eighty (180) days of the end of each fiscal year end, You will provide Us with audited financial statements accompanied by an audit report and an unqualified opinion of the independent certified
public accountants. Notwithstanding any term or condition contained in this Warrant Agreement to the contrary, Your failure to comply with this paragraph shall not constitute a default unless You have not provided the information requested within
ten (10) days of Our request. 

  

	Þ	 You shall submit to Us any other documents and other information that We may reasonably request from
time to time and are necessary to implement the provisions and purposes of this Warrant Agreement. 

  

	10.	 REGISTRATION RIGHTS UNDER THE 1933 ACT. 

The shares of Your Common Stock into which the Warrant Stock is convertible shall be entitled to “piggyback” and
S-3 registration rights on the same terms, conditions, limitations and obligations imposed upon other holders of Your Preferred Stock, all as set forth in the Rights Agreement. The provisions set forth in the
Rights Agreement relating to such registration rights in effect as of the date of this Warrant Agreement may not be amended, modified or waived without Our prior written consent unless such amendment, modification or waiver affects the rights
associated with the shares of common stock into which the Warrant Stock is convertible in the same manner as such amendment, modification, or waiver affects the rights associated with all other shares of the same series and class of stock as the
Warrant Stock. 
  

	11.	 OTHER LEGAL PROVISIONS THE PARTIES WILL ABIDE BY. 

Effective Date. This Warrant Agreement shall be construed and shall be given effect in all respects as if it had been executed and delivered by the
Parties on the date hereof. This Warrant Agreement shall be binding upon any of the successors or assigns of the Parties. 
 Attorney’s Fees. In
any litigation, arbitration or court proceeding between the Parties relating to this Warrant Agreement, the prevailing party shall be entitled to reasonable attorneys’ fees and expenses and reasonable costs of proceedings incurred in enforcing
this Warrant Agreement. 

  

			
	Warrant (Loan) 0970-W-01	  	11

 Governing Law. This Warrant Agreement shall be governed by and construed for all purposes under and
in accordance with the laws of the State of California without giving effect to that body of law pertaining to conflicts of laws. 
 Consent to
Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Warrant Agreement may be brought in any state or federal court of competent jurisdiction located in the State of California. By execution and delivery of
this Warrant Agreement, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in San Mateo County, State of California; (b) waives any objection as to jurisdiction or venue in San Mateo County, State of
California; and (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts. Service of process on any party hereto in any action arising out of or relating to this Warrant Agreement shall be effective if
given in accordance with the requirements for notice set forth in this Section, and shall be deemed effective and received as set forth therein. Nothing herein shall affect the right to serve process in any other manner permitted by law or shall
limit the right of either party to bring proceedings in the courts of any other jurisdiction. 
 Mutual Waiver of Jury Trial; Judicial Reference.
Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert person and the Parties wish applicable state and federal laws to apply (rather than arbitration
rules), The Parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF THE PARTIES SPECIFICALLY WAIVES ANY RIGHT THEY MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD
PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY YOU AGAINST US OR OUR ASSIGNEE OR BY US OR OUR ASSIGNEE AGAINST YOU WITH RESPECT TO THIS WARRANT AGREEMENT. IN THE EVENT THAT THE FOREGOING JURY TRIAL WAIVER IS NOT
ENFORCEABLE, ALL CLAIMS, INCLUDING ANY AND ALL QUESTIONS OF LAW OR FACT RELATING THERETO, SHALL, AT THE WRITTEN REQUEST OF ANY PARTY, BE DETERMINED BY JUDICIAL REFERENCE PURSUANT TO THE CALIFORNIA CODE OF CIVIL PROCEDURE. THE PARTIES SHALL MUTUALLY
SELECT A SINGLE NEUTRAL REFEREE, WHO SHALL BE A RETIRED STATE OR FEDERAL JUDGE. IN THE EVENT THAT THE PARTIES CANNOT AGREE UPON A REFEREE, THE REFEREE SHALL BE APPOINTED BY THE COURT. THE REFEREE SHALL REPORT A STATEMENT OF DECISION TO THE COURT.
NOTHING IN THIS SECTION SHALL LIMIT THE RIGHT OF ANY PARTY AT ANY TIME TO EXERCISE LAWFUL SELF-HELP REMEDIES, FORECLOSE AGAINST COLLATERAL OR OBTAIN PROVISIONAL REMEDIES. THE PARTIES SHALL BEAR THE FEES AND EXPENSES OF THE REFEREE EQUALLY UNLESS THE
REFEREE ORDERS OTHERWISE. THE REFEREE SHALL ALSO DETERMINE ALL ISSUES RELATING TO THE APPLICABILITY, INTERPRETATION, AND ENFORCEABILITY OF THIS SECTION. THE PARTIES ACKNOWLEDGE THAT THE CLAIMS WILL NOT BE ADJUDICATED BY A JURY. This waiver extends
to all such Claims, including Claims that involve persons other than You and Us; Claims that arise out of or are in any way connected to the relationship between You and Us; and any Claims for damages, breach of contract, specific performance, or
any equitable or legal relief of any kind, in each case arising out of this Warrant Agreement. 

  

			
	Warrant (Loan) 0970-W-01	  	12

 Counterparts. This Warrant Agreement may be executed in two or more counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument. 
 Notices. Any notice required or permitted under
this Warrant Agreement shall be given in writing and shall be deemed effectively given upon the earlier of (1) actual receipt or 3 days after mailing if mailed postage prepaid by regular or airmail to Us or You or (2) one day after it is
sent by overnight mail via nationally recognized courier or (3) on the same day as sent via confirmed facsimile transmission, provided that the original is sent by personal delivery or mail by the sending party. 

Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce
its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where such party will not have an adequate
remedy at law and where damages will not be readily ascertainable. Each party expressly acknowledges and agrees that there is no adequate remedy at law for any breach of this Warrant Agreement and that in the event of any breach of this Warrant
Agreement, the injured party shall be entitled to specific performance of any or all provisions hereof or an injunction prohibiting the other party from continuing to commit any such breach of this Warrant Agreement. 

Survival. The representations, warranties, covenants, and conditions of the Parties contained herein or made pursuant to this Warrant Agreement shall
survive the execution and delivery of this Warrant Agreement. 
 Severability. In the event any one or more of the provisions of this Warrant
Agreement shall for any reason be held invalid, illegal or unenforceable, the remaining provisions of this Warrant Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid,
legal and enforceable provision, which comes closest to the intention of the Parties underlying the invalid, illegal or unenforceable provision. 

Entire Agreement. This Warrant Agreement constitutes the entire agreement between the Parties pertaining to the subject matter contained in it and
supersedes all prior and contemporaneous agreements, representations and undertakings of the Parties, whether oral or written, with respect to such subject matter. 

Amendments. Any provision of this Warrant Agreement may only be amended by a written instrument signed by the Parties. 

Lost Warrants or Stock Certificates. You covenant to Us that, upon receipt of evidence reasonably satisfactory to You of the loss, theft, destruction
or mutilation of this Warrant Agreement or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to You, or in the case of any such mutilation upon surrender and
cancellation of such Warrant Agreement or stock certificate, You will make and deliver a new Warrant Agreement or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant Agreement or stock certificate. 

Rights as Stockholders. We shall not, as a party to this Warrant Agreement, be entitled to vote or receive dividends or be deemed the holder of the
Warrant Stock or any of Your other securities which may at any time be issuable upon the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon Us any of the rights of one of Your

  

			
	Warrant (Loan) 0970-W-01	  	13

 
stockholders or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to receive dividends or subscription rights or otherwise
until this Warrant Agreement is exercised and the shares purchasable upon the exercise hereof shall have become deliverable, as provided herein. 

Signatures. This Warrant Agreement may be executed and delivered by facsimile or transmitted electronically in either Tagged Image Format Files
(“TIFF”) or Portable Document Format (“PDF”) and, upon such delivery, the facsimile, TIFF or PDF signature, as applicable, will be deemed to have the same effect as if the original signature had been delivered to
the other party. 
 (Signature Page to Follow) 

  

			
	Warrant (Loan) 0970-W-01	  	14

 IN WITNESS WHEREOF, each of the Parties have caused this Warrant Agreement to be executed by its
officers who are duly authorized as of the Effective Date. 
  

			
	You:	 	BERKELEY LIGHTS, INC.
		
	Signature:	 	/s/ Igor Khandros
		
	Print Name:	 	Igor Khandros
		
	Title:	 	CEO

  

			
	Us:	 	TRIPLEPOINT CAPITAL LLC
		
	Signature:	 	 
		
	Print Name:	 	 
		
	Title:	 	 

 [SIGNATURE PAGE TO WARRANT AGREEMENT
0970-W-01] 

 IN WITNESS WHEREOF, each of the Parties have caused this Warrant Agreement to be executed by its
officers who are duly authorized as of the Effective Date. 
  

			
	You:	 	BERKELEY LIGHTS, INC.
		
	Signature:	 	 
		
	Print Name:	 	 
		
	Title:	 	 
		
	Us:	 	TRIPLEPOINT CAPITAL LLC
		
	Signature:	 	/s/ Harold Zagunis
		
	Print Name:	 	Harold Zagunis
		
	Title:	 	CFO

 [SIGNATURE PAGE TO WARRANT AGREEMENT
0970-W-01] 

  

			
	Warrant (Loan) 0970-W-01	  	16

 EXHIBIT I 

NOTICE OF EXERCISE 
  

	To:	 [________________________] 

 

	1.	 We hereby elect to purchase [______] shares of the Series [______] Preferred Stock of [______], pursuant to the
terms of the Plain English Warrant Agreement dated the [______] day of [______], [20__] (the “Plain English Warrant Agreement”) between You and Us, We hereby tender here payment of the purchase price for such shares in full, together with
all applicable transfer taxes, if any. 

  

	2.	 Method of Exercise (Please initial the applicable blank) 

 

	 	a.	 ______ The undersigned elects to exercise the Plain English Warrant Agreement by means of a cash payment, and
gives You full payment for the purchase price of the shares being purchased, together with all applicable transfer taxes, if any. 

  

	 	b.	 ______ The undersigned elects to exercise the Plain English Warrant Agreement by means of the Net Issuance
Exercise method of Section 3 of the Plain English Warrant Agreement. 

  

	3.	 In exercising Our rights to purchase the Series [______] Preferred Stock of [____________], We hereby
confirm and acknowledge the investment representations, warranties and covenants made in Section 7 of the Plain English Warrant Agreement. 

Please issue a certificate or certificates representing these purchased shares of Series [______] Preferred Stock in Our name or in such other name as
is specified below. 
  

			
	 (Name)
  

	(Address)
		
	US:	 	TRIPLEPOINT CAPITAL LLC
		
	By:	 	 
		
	Title:	 	 
		
	Date:	 	 

  

			
	Warrant (Loan) 0970-W-01	  	17

 EXHIBIT II 

ACKNOWLEDGMENT OF EXERCISE 

[____________], hereby acknowledges receipt of the “Notice of Exercise” from TRIPLEPOINT CAPITAL LLC, to purchase [______] shares of the Series
[______] Preferred Stock of [______], pursuant to the terms of the Plain English Warrant Agreement, and further acknowledges that [______] shares remain subject to purchase under the terms of the Plain English Warrant Agreement. 

 

			
	YOU:	 	BERKELEY LIGHTS, INC.
		
	By:	 	 
		
	Title:	 	 
		
	Date:	 	 

  

			
	Warrant (Loan) 0970-W-01	  	18

 EXHIBIT III 

TRANSFER NOTICE 
 FOR VALUE
RECEIVED, the foregoing Plain English Warrant Agreement and all rights evidenced thereby are hereby transferred and assigned to 
  

			
	(Please Print)	  	 
		
	Whose address is	  	 
		
	    	  	 

  

			
	Dated:	 	 
		
	Holder’s Signature:	 	 
		
	Holder’s Address:	 	 
		
	Transferee’s Signature:	 	 
		
	Transferee’s Address:	 	 
		
	Signature Guaranteed:	 	 

 NOTE: The signature to this Transfer Notice must correspond with the name as it appears on the face of the Plain
English Warrant Agreement, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Plain
English Warrant Agreement. 
 By signature hereto, Transferee agrees to be subject to and bound by the terms and conditions of (i) the Plain English
Warrant Agreement, including the investment representations, warranties and covenants contained in Section 7 thereof and (ii) Section 3.11 (Market Standoff Agreement) of the Rights Agreement. Transferee also agrees to execute the form
of lock-up letter requested by the underwriters of Berkeley Lights, Inc.’s initial public offering. Notwithstanding the foregoing, in no event shall such market
stand-off provisions or lock-up letter restrict Our ability to exercise Our purchase rights under this Warrant Agreement, including the transfer of Common Stock to You
solely to satisfy the exercise price pursuant to the Net Issuance Method. 

  

			
	Warrant (Loan) 0970-W-01	  	19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]